document_id,Product Name,Patent No.,Company,Reg Rev Period,Testing Phase,Approval Phase,IND/IDE Filing Date,NDA/PMA Filing Date,Approval Date,Application No.,Pat term ext
00-1871,"ZiagenTM
                     (abacavir","5,034,394","Glaxo Wellcome, Inc",1632,1455,177,,,"December 17, 1998","the new drug application (NDA) for ZiagenTM
                     (NDA 20-977)",906
00-1874,"VitraveneTM
                     (fomivirsen sodium","4,689,320","Isis Pharmaceuticals, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",1738,1598,140,,,"August 26, 1998",NDA 30-961,954
00-1875,"AzoptTM
                     (brinzolamide","5,378,703","Alcon Laboratories, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",2049,1620,429,,,"April 1, 1998","the new drug application (NDA) for AzoptTM
                     (NDA 20-816)",579
00-1865,"Maxalt
                    ®
                     (rizatriptan benzoate","5,298,520",Merck & Co,2099,1734,365,"October 1, 1992",,"June 29, 1998",the date the investigational new drug application became effective,153
00-1868,"Plavix
                    ®
                     (clopidogrel bisulfate","4,847,265","Sanofi Pharmaceuticals, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",2755,2551,204,"May 5, 1990",,"November 17, 1997",the date the investigational new drug application became effective,1374
00-1870,"Refludan
                    ®
                     (lepirudin","5,180,668","Hoechst AG, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",1149,718,431,"January 14, 1995",,"March 6, 1998",the date the investigational new drug application became effective,777
00-1867,"Arava
                    ®
                     (leflunomide","4,284,786","Hoechst Aktiengesellschaft, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",2032,1908,124,,,"September 10, 1998","the new drug application (NDA) for Arava
                    ®
                     (NDA 20-905)",1110
00-1872,"GlucaGen
                    ®
                     (glucagon (rDNA origin","4,826,763","Novo Nordisk A/S, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",2569,2296,273,,,"June 22, 1998",NDA 20-918,1423
00-1873,,"5,405,363",Angieon Corp,200020101030,603,427,,,"August 19, 1998","the premarket approval application (PMA) for Sentinel Model 2000/2010
                    ®
                     (PMA P970024)",132
00-2030,Teslascan (magnafodipir trisodium,"4,933,456","Nycomed Salutar, Inc",3129,2325,804,,,"November 26, 1997",NDA 20-652,
00-2031,,"4,762,710","Amvax, Inc",2578,1542,1036,,,"July 29, 1998","the product license application (PLA) for CertivaTM
                     (PLA 95-1529)",1826
00-2032,,"4,834,757","DePuy AcroMed, Inc",2631,1708,923,,,"February 2, 1999","the date the investigational device exemption (IDE) required under section 520(g) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360j(g)) for human tests to begin became effective November 22, 1991.
                

                    2. 
                    The date the application",1776
00-2243,,"4,704,275",American Home Products Corp,3804,3226,578,"April 3, 1988",,"August 31, 1998",the date the investigational new drug application became effective,1826
00-2149,,"4,485,088","Alaco, Inc",5845,5734,111,,,"June 10, 1998",NADA 141-107,1825
00-3172,,"4,954,126",Boston Scientific Corp,1533,1351,182,,,"September 29, 1998","the date the investigational device exemption (IDE) required under section 520(g) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360j(g)) for human tests to begin became effective July 21, 1994.
2. The date the application",857
00-12117,,,,,1730,1507,,,,,1761
01-681,,"4,713,448","Biomatrix, Inc",2047134482949,1783,1166,,,"August 8, 1997","the date the investigational device exemption (IDE) required under section 520(g) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360j(g)) for human tests to begin became effective July 14, 1989. 
                

                    2. 
                    The date the application",396
01-683,,"5,143,724","Biomatrix, Inc",2051437242949,1783,1166,,,"August 8, 1997","the date the investigational device exemption (IDE) required under section 520(g) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360j(g)) for human tests to begin became effective July 14, 1989. 
                

                    2. 
                    The date the application",396
01-974,,"5,099,013","Biomatrix, Inc",2050990132949,1783,1166,,,"August 8, 1997","the date the investigational device exemption (IDE) required under section 520(g) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360j(g)) for human tests to begin became effective July 14, 1989. 
                

                    2. 
                    The date the application",396
01-5513,"Aciphex
                    TM
                    
                     (rabeprazole sodium","5,045,552",Eisai Co,2922,2415,507,"August 21, 1991",,"August 19, 1999",the date the investigational new drug application became effective,1713
01-5812,Provigil (modafinil,"4,177,290","Cephalon, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",1975,1250,725,"July 30, 1993",,"December 24, 1998",the date the investigational new drug application became effective,985
01-11961,Baycol (cerivastatin sodium,"5,006,530",Bayer Corp,2262,1896,366,"April 19, 1991",,"June 26, 1997",the date the investigational new drug application became effective,890
01-12025,,"4,695,623","Amgen, Inc",4394,3849,545,"September 27, 1985",,"October 6, 1997",the date the investigational new drug application became effective,1826
01-12093,Xenical (orlistat,"4,598,089","HLR Technology Corporation, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",3969,3091,878,,,"April 23, 1999",NDA 20-766,1824
01-12228,,"4,477,615",3V Partecipazioni Industriali S,883482,684,,,,,the test,1827
01-17105,Detrol (tolterodine tartrate,"5,382,600","Pharmacia & Upjohn Atiebolag, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",1267,901,366,"October 7, 1994",,"March 25, 1998",the date the investigational new drug application became effective,64
01-17103,Gabitril (tiagabine hydrochloride,"5,010,090","Novo Nordisk A/S, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",2346,1651,695,,"November 6, 1995","September 30, 1997",NDA 20-646,1255
01-23703,Synercid (quinupristin and dalfopristin,"4,798,827",Rhone Poulenc Rorer S,2793,2046,747,"January 30, 1992",,"September 21, 1999",the date the investigational new drug application became effective,1770
01-23700,Kaletra (lopinavir,"5,886,036","Abbott Laboratories, Inc",1397,1290,107,,"June 1, 2000","September 15, 2000",the new drug application (NDA) for Kaletra (NDA 21-226),324
01-23701,Synercid (quinupristin and dalfopristin,"4,668,669",Rhone Poulenc Rorer S,1919,1172,747,,"September 5, 1997","September 21, 1999",the new drug application (NDA) for Synercid (NDA 50-747),1333
01-23702,Rescula (unoprostone isopropyl ester,"5,221,763","R-Tech Veno, Ltd",1347,1186,161,,"February 25, 2000","August 3, 2000",NDA 21-214,774
01-23750,Trileptal (oxcarbazepine,"4,559,174","Novartis, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",2523,2046,477,,"September 25, 1998","January 14, 2000",the new drug application (NDA) for Trileptal (NDA 21-014),1690
01-24126,,"5,385,732","Genetech, Inc",1990,1741,249,,,"June 2, 2000",the product license application (BLA) for TNKase (BLA 99-0903),853
01-25998,,,,,,,,,,,
02-1320,,"5,125,926","PLC Medical Systems, Inc",3135,2586,549,,,"August 20, 1998",the premarket approval application (PMA) for the Heart Laser System (PMA P950015),695
02-1723,,"4,291,708",Transcan Research and Development Co,20001595,964,631,,,"April 16, 1999","the date the investigational device exemption (IDE) required under section 520(g) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360j(g)) for human tests to begin became effective December 5, 1994.
                

                    2. 
                    The date the application",1826
02-1925,SONATA (zaleplon,"4,626,538",American Cyanamid Co,3027,2435,592,,,"August 13, 1999",NDA 20-859,1835
02-1926,MIFEPREX (mifepristone,"4,386,085","the Population Council, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",2249,593,1656,,,"September 28, 2000",the new drug application (NDA) for MIFEPREX (NDA 20-687),1825
02-1927,KEPPRA (Levetiracetam,"4,943,639","UCB Societe Anonyme, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",2010,1707,303,,,"November 30, 1999",NDA 21-035,1155
02-2671,,"4,868,112","the Genetics Institute, Inc",1751,987,764,,,"March 6, 2000",the product license application (PLA) for REFACTO (PLA 98-0137),1475
02-4382,Celexa (citalopram hydrobromide,"4,650,884",H,5498,5061,437,,"May 7, 1997","July 17, 1998",the new drug application (NDA) for Celexa (NDA 20-822),1826
02-4383,,"4,594,401",Menicon Co,1917,1435,482,,,"July 11, 2000",the premarket approval application (PMA) for Menicon Z Rigid Gas Permeable Contact Lens (PMA P990018),1205
02-4596,RELENZA (zanamivir,"5,360,817","Glaxo Wellcome, Inc",1800,1527,273,"August 23, 1994","October 27, 1998","July 26, 1999",the date the investigational new drug application became effective,1001
02-4681,NEXIUM (esomeprazole magnesium,"4,738,974","Astrazenica, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",1284,838,446,"August 18, 1997","December 3, 1999","February 20, 2001",the date the investigational new drug application became effective,865
02-4683,REMINYL (galatamine hydrobromide,"4,663,318","Janssen Research Foundation, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",1608,1089,519,,"September 29, 1999","February 28, 2001",the new drug application (NDA) for REMINYL (NDA 21-169),1063
02-4682,EVISTA(raloxifene hydrochloride,"4,418,068",Eli Lilly and Co,5412,5228,184,"February 16, 1983",,"December 9, 1997",the date the investigational new drug application became effective,1103
02-4685,ABREVA (docosanol,"4,874,794","Avanir Pharmaceuticals, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",3270,2323,947,,,"July 25, 2000",the new drug application (NDA) for ABREVA (NDA 20-941),1825
02-4748,AVELOX (moxifloxacin hydrochloride,"4,490,517",Bayer Corp,1435,1069,366,,,"December 10, 1999",the new drug application (NDA) for AVELOX (NDA 21-085),889
02-4747,,"4,690,951",Eli Lilly & Co,5707,1211,4496,,,"December 22, 1999",the date the investigational new animal drug application (INAD) became effective,1095
02-4684,TRAVATAN (travoprost,"5,889,052","Alcon Laboratories, Inc",1694,1441,253,"July 28, 1996",,"March 16, 2001",the date the investigational new drug application became effective,484
02-4889,HECTOROL (doxercalciferol,"4,555,364","The Wisconsin Alumni Research Foundation, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",4072,3614,458,,,"June 9, 1999",NDA 20-862,1824
02-4965,,"4,968,514",BF Goodrich Co,1326,739,,,,,the test,962
02-9364,,,,,,1656,,,,,
02-12092,ACTOS (proglitazone hydrochloride,"4,687,777","Takeda Chemical Industries, Ltd",3556,3374,182,"October 21, 1989","January 15, 1999","July 15, 1999",the date the investigational new drug application became effective,1826
02-12784,COMTAN (entacapone,"5,446,194",Orion Corp,2937,2281,656,,"January 2, 1998","October 19, 1999",the new drug application (NDA) for COMTAN (NDA 20-796),416
02-13227,,"5,712,155",Immunex Corp,2322,2143,179,"June 26, 1992",,"November 2, 1998",the date the investigational new drug application became effective,240
02-16052,BETAXON (levobetaxolol,"4,911,920","Alcon Laboratories, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",947,765,182,,,"February 23, 2000",NDA 21-114,579
02-17781,Protonix (pantoprazole sodium,"4,758,579","BYK Gulden Lomerg Chemische Fabrik GmbH, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",3401,2818,583,"October 13, 1990","June 30, 1998","February 2, 2000",the date the investigational new drug application became effective,
02-17782,Axert (almotriptan malate,"5,565,447",Almirall Prodesfarma S,1348,843,505,,"December 20, 1999","May 7, 2001",the new drug application (NDA) for Axert (NDA 20-001),569
02-17783,,"5,951,974",Schering Corp,1271,877,394,,,"January 19, 2001",BLA 99-1488,435
02-17904,,"5,444,106","Pharmacia AB, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",9111594,1101,493,,,"April 5, 2001","the date the investigational device exemption (IDE) required under section 520(g) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360j(g)) for human tests to begin became effective November 25, 1996.
                

                    2. 
                    The date the application",956
02-18975,Definity (perflutren lipid microspheres,"5,527,521","Dupont Contrast Imaging, Inc",2160,1193,967,,"December 8, 1998","July 31, 2001",the new drug application (NDA) for Definity (NDA 21-064),1418
02-27096,,,,6318,4662,1656,,,"September 28, 2000",the new drug application (NDA) for MIFEPREX (NDA 20-687),
02-28883,LOTRONEX (alosetron hydrochloride,"5,360,800","Glaxo Wellcome, Inc",3564,3339,225,"May 10, 1990",,"February 9, 2000",the date the investigational new drug application became effective,1076
02-28885,SOLAGE (mequinol,"5,194,247",Bristol-Myers Squibb Co,2689,1978,711,,,"December 10, 1999",the new drug application (NDA) for SOLAGE (NDA 20-922),1365
02-28882,COLAZAL (balsalzide disodium,"4,412,992","Biorex Laboratories Unlimited, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",2950,1828,1122,,,"July 18, 2000",the new drug application (NDA) for COLAZAL (NDA 20-610),1825
02-28884,ACOVA (argatroban,"5,214,052",Texas Biotechnology Corp,4022,2971,1051,,"August 15, 1997","June 30, 2000",NDA 20-883,839
02-29187,GLEEVEC (imatinib mesylate,"5,521,184",Novartis Corp,1098,1025,73,,,"May 10, 2001",the new drug application (NDA) for GLEEVEC (NDA 21-335),599
02-29188,EVOXAC (Cevimeline HCI,"4,855,290","the State of Israel, Israel Institute for Biological Research, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",1733,1230,503,,,"January 11, 2000",NDA 20-989,1133
03-1567,,"4,784,950","ZymoGenetics, Inc",3954,2904,1050,"May 29, 1988",,"March 25, 1999",the date the investigational new drug application became effective,1826
03-2970,TEMODAR (temozolomide,"5,260,291",Schering Corp,2032,1668,364,,"August 13, 1998","August 11, 1999",NDA 21-029,1136
03-3556,Rapamune (sirolimus (also rapamycin,"5,100,899","Sir Roy Caine, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",2709,2434,275,"April 17, 1992",,"September 15, 1999",the date the investigational new drug application became effective,1492
03-3555,Avandia (rosiglitazone maleate,"5,002,953",Smithkline Beecham Corp,2042,1859,183,,,"May 25, 1999",the new drug application (NDA) for Avandia (NDA 21-071),1021
03-3872,VALCYTE (valganciclovir hydrochloride,"6,083,953","Syntex, and the Patent and Trademark Of0fice requested FDA's assistance in determining this patent's eligibility for patent term restoration",2101,1919,182,,"September 29, 2000","March 29, 2001",NDA 21-304,
03-3873,CANCIDAS (caspofungin acetate,"5,514,650",Merck & Co,1974,1791,183,,"July 28, 2000","January 26, 2001",the new drug application (NDA) for CANCIDAS (NDA 21-227),682
03-4567,Starlix (nateglinide,"34,878","Novartis, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",2147,1775,372,,,"December 22, 2000",the new drug application (NDA) for Starlix (NDA 21-204),1259
03-4691,ZOMETA (zoledronic acid,"4,939,130",Novartis Corp,2810,2201,609,,,"August 20, 2001",the new drug application (NDA) for ZOMETA (NDA 21-223),1752
03-6226,,,,,757,2126,,,"September 30, 1997",the premarket approval application (PMA) for VITREON (PMA P910068),1826
03-6490,PRECEDEX (dexemedetomidine,"4,910,214",Orion Corp,3894,3529,365,,,"December 17, 1999",the new drug application (NDA) for PRECEDEX (NDA 21-038),3919
03-6507,TOPAMAX (topiramate,"4,513,006","McNeilab, Inc",3844,2984,860,,,"December 24, 1996",the new drug application (NDA) for TOPAMAX (NDA 20-505),1826
03-6892,,"4,793,353","Advanced Neuromodulation Systems, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",469,292,177,,,"November 21, 2001",PMA P010032,840
03-7280,TEQUIN (gatifloxacin,"4,980,470",Kyorin Pharmaceutical Co,1087,732,355,,,"December 17, 1999",the new drug application (NDA) for TEQUIN (NDA 21-061),720
03-7711,LEVULAN KERASTICK (aminolevulinic acid HCl,"5,079,262","DUSA Pharmaceuticals, Inc",2528,2007,521,"January 2, 1993",,"December 3, 1999",the date the investigational new drug application became effective,1524
03-7819,,"5,532,221","Lifecore Medical, Inc",2438,1453,985,,,"November 16, 2001","the date the investigational device exemption (IDE) required under section 520(g) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360j(g)) for human tests to begin became effective March 17, 1995.
                

                    2. 
                    The date an application",867
03-7820,,"5,258,494",Stryker Corp,13627,3485,142,,,"October 17, 2001","the date the investigational device exemption (IDE) required under section 520(g) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360j(g)) for human tests to begin became effective November 14, 1991.
                

                    2. 
                    The date the application",1837
03-9536,FASLODEX (fulvestrant,"4,659,516","AstraZeneca UK, Ltd",1935,1541,394,,"March 28, 2001","April 25, 2002",the new drug application (NDA) for FASLODEX (NDA 21-344),1165
03-9534,ZETIA (ezetimibe,"37,721",Schering Corp,1983,1680,303,"May 23, 1997","December 27, 2001","October 25, 2002",the date the investigational new drug application became effective,497
03-9535,,"4,976,709","Sunrise Technologies International, Inc",3047,2806,241,,,"June 30, 2000","the date the investigational device exemption (IDE) required under section 520(g) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360j(g)) for human tests to begin became effective February 28, 1992.
                

                    2. 
                    The date the application",1644
03-9577,VFEND (voriconaxole,"5,567,817","Pfizer, Inc",2452,1898,554,,,"May 24, 2002",the new drug application (NDA) for VFEND (NDA 21-266),945
03-9578,TIKOSYN (methanesulfonamide,"4,959,366","Pfizer, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",3350,2778,572,"August 1, 1990","March 9, 1998","October 1, 1999",the date the investigational new drug application became effective,1827
03-9809,IMAGENT (perfluorohexane and DMPC,"5,639,443",Alliance Pharmaceutical Corp,2264,1303,961,,"October 14, 1999","May 31, 2002",NDA 21-191,423
03-9694,,"5,776,456",IDEC Pharmaceuticals Corp,3363,2887,476,"December 7, 1992",,"February 19, 2002",the date the investigational new drug application became effective,227
03-9663,EXELON (rivastigmine tartrate,"4,948,807","Novartis, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",3424,2313,1111,,"April 7, 1997","April 21, 2000",the new drug application (NDA) for EXELON (NDA 20-823),1825
03-10298,AROMASIN (exemestane,"4,808,616","Pharmacia and Upjohn, S",3153,2848,305,,,"October 21, 1999",the new drug application (NDA) for AROMASIN (NDA 20-753),1745
03-10302,,"5,360,897","the University of Rochester through American Home Products, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",1910,1648,262,,,"February 17, 2000",the product license application (PLA) for PREVNAR (PLA 99-0279),1086
03-11215,TRACLEER (bosentan,"5,292,740","Hoffman-La Roche, Inc",2176,1807,369,,,"November 20, 2001",the new drug application (NDA) for TRACLEER (NDA 21-290),1259
03-19446,BENICAR (olmesartan medocomil,"5,616,599","Sankyo Company, Ltd",2522,1882,640,,"July 25, 2000","April 25, 2002",the new drug application (NDA) for BENICAR (NDA 21-286),756
03-19621,SPECTRACEF (cefditoren pivoxil,"4,839,350","Meiji Seika Kaisha, Ltd",1461,851,610,,"December 29, 1999","August 29, 2001",the new drug application (NDA) for SPECTRACEF (NDA 21-222),1032
03-29333,,,Eli Lilly & Co,2493,2193,300,,,"November 21, 2001",the biological license application (BLA) for XIGRIS (BLA 125029/0),1397
03-29464,ABILIFY (aripiprazole,"5,006,528",Otsuka Pharmaceutical Co,3416,3035,381,,,"November 15, 2002",the new drug application (NDA) for ABILIFY (NDA 21-436),
03-29742,,"5,521,207",G,1675,1578,,,,"August 21, 2002",the new animal drug application (NADA) for DERAMAXX (NADA 141-203),882
03-29927,LEXAPRO (escitalopram oxalate,"34,712",H,1146,636,510,"June 27, 1999","March 23, 2001","August 14, 2002",the date the investigational new drug application became effective,827
03-29929,INVANZ (ertapenem sodium,"5,478,820",Syngenta Ltd,2273,1916,357,,"November 30, 2000","November 21, 2001",the new drug application (NDA) for INVANZ (NDA 21-337),1023
03-29928,ELOXATIN (oxaliplatin,"5,420,319","Sanofi-Synthelabo, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",3417,3370,47,,"June 24, 2002","August 9, 2002",NDA 21-492,1138
03-30028,STRATTERA (atomoxetine hydrochloride,"5,658,590,",Eli Lilly & Co,7718,7307,411,"October 11, 1981","October 12, 2001","November 26, 2002",the date the investigational new drug application became effective,685
E4-130,LUMIGAN (bimatoprost,"5,688,819","Allergan, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",1967,1787,180,,"September 18, 2000","March 16, 2001",the new drug application (NDA) for LUMIGAN (NDA 21-275),907
04-1841,REMODULIN (treprostinil sodium,"5,153,222","United Therapeutics, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",4026,3443,583,"May 15, 1991","October 16, 2000","May 21, 2002",the date the investigational new drug application became effective,337
04-1840,"FROVA 
                    

      ( print page 4306",,"Vernalis, Ltd",2201,1186,1015,"November 1, 1995","January 29, 1999","November 8, 2001",the date the investigational new drug application became effective,
04-2546,EXTRANAEAL (icodextrin,"4,761,237","Baxter International, Inc",2207,1478,729,"December 6, 1996",,"December 20, 2002",the date the investigational new drug application became effective,1467
04-2547,ORTHO-EVRA (norelgestromin/ethinyl estradiol transdermal system,"5,876,746","Johnson and Johnson, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",2001,1666,335,,,"November 20, 2001",the new drug application (NDA) for ORTHO-EVRA (NDA 21-180),664
04-5758,ZELNORM (tegaserod maleate,"5,510,353","Novartis Pharmaceuticals, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",2826,1931,895,"October 30, 1994","February 11, 2000","July 24, 2002",the date the investigational new drug application became effective,1888
04-5703,IPRIVASK (desirudin,"4,745,177",Novartis Corp,4707,3696,1011,"May 17, 1990","June 28, 2000","April 4, 2003",the date the investigational new drug application became effective,
04-5760,,"5,356,804","Genzyme, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",1843,807,1036,"April 9, 1998",,"April 24, 2003",the date the investigational new drug application became effective,1438
04-5759,FACTIVE (gemifloxacin mesylate,,"LG Life Sciences, and the Patent and Trademark Office requested FDA's assistance in determining these patents' eligibility for patent term restoration",2038,832,1206,"September 6, 1997","December 16, 1999","April 4, 2003",the date the investigational new drug application became effective,
04-6159,VELCADE bortezomib,"5,780,454","Millenium Pharmaceuticals, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",1723,1610,113,,"January 21, 2003","May 13, 2003",the new drug application (NDA) for VELCADE (NDA 21-602),920
04-15275,,"5,480,668",The NutraSweet Co,3143,1503,,,,,the test,973
04-15274,,"5,667,787","Aventis Pasteur, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",3591,1415,2176,"July 16, 1992",,"May 14, 2002",the date the investigational new drug application became effective,242
04-15301,,,"Technology Transfer, Inc",4222,4188,,,,"March 17, 2003",NADA 141-217,
04-15569,,"5,382,518","Sanofi-Synthelabo, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",2360,1420,940,"January 27, 1996",,"July 12, 2002",the date the investigational new drug application became effective,1638
04-15712,XOPENEX (levalbuterol,"5,362,755","Sepracor, Inc",1458,824,634,,"June 30, 1997","March 25, 1999",the new drug application (NDA) for XOPENEX (NDA 20-837),502
04-15802,,"5,545,403","Millenium and Ilex Partners, L",3423,2921,502,"December 25, 1991",,"May 7, 2001",the date the investigational new drug application became effective,632
04-17209,,"4,703,752","Shlome Gabbay, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",5596,5418,178,,,"March 14, 2002","the date the investigational device exemption required under section 520(g) of the act for human tests to begin became effective November 19, 1986.
                

                    2. 
                    The date the application",1825
04-21625,REYATAZ (atazanavir sulfate,"5,849,911",Novartis Corp,1723,1540,183,,"December 20, 2002","June 20, 2003",the new drug application (NDA) for REYATAZ (NDA 21-567),72
04-21678,VISUDYNE (verteporfin,"5,095,030","University of British Columbia, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",3194,2953,241,,"August 16, 1999","April 12, 2000",NDA 21-119,
04-21675,,"5,075,222","Amgen, Inc",4101,3413,688,,,"November 14, 2001",BLA 103950,1825
04-21749,,"4,963,489","Advanced Tissue Sciences, Inc",4050,3650,400,,,"September 28, 2001",PMA P00036,
04-21874,,"5,547,853","Biogen, Inc",2104,1618,486,"April 29, 1997",,"January 30, 2003",the date the investigational new drug application became effective,1259
04-24378,GANIRELIX ACETATE INJECTION (ganirelix acetate,"4,801,577","Syntex, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",3558,3376,182,,,"July 29, 1999",NDA 21-057,
05-8587,GEODON (ziprasidone hydrochloride,"4,831,031","Pfizer, Inc",3933,2511,1422,,"March 17, 1997","February 5, 2001",the date the Investigational New Drug application became effective,1825
05-9462,ERTACZO (sertaconazole nitrate,"5,135,943","Ferrer Internacional, S",2718,1914,804,,,"December 10, 2003",the new drug application (NDA) for ERTACZO (NDA 21-385),1776
05-14695,CLARINEX (desloratadine,"4,659,716",Schering Corp,1354,561,793,"April 9, 1998","October 21, 1999","December 21, 2001",the date the investigational new drug application became effective,1074
05-14748,,"5,354,330","ATS Medical, Inc",1418,980,438,,,"October 13, 2000","the date the investigational device exemption (IDE) required under section 520(g) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360j(g)) for human tests to begin became effective November 27, 1996.
                

                    2. 
                    The date the application",505
05-14921,,"4,826,868","Johnson & Johnson, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",2347,1887,,,,"March 31, 2003",NADA 141-193,1405
05-22012,,,,,,,,,,,
E6-1050,SPIRIVA HANDIHALER (tiotropium bromide monohydrate,"5,610,163","Boehringer Ingelheim Corporation, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",3318,2557,761,,,"January 30, 2004",the new drug application (NDA) for Spiriva HandiHaler (NDA 21-395),1421
E6-1072,ENABLEX (darifenacin hydrobromide,"5,096,890",Novartis International Phamaceutical Ltd,3824,3073,751,,,"December 22, 2004",NDA 21-513,2298
E6-1078,,"6,267,958","Genentech, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",3440,2329,1111,"January 20, 1994",,"June 20, 2003",the date the investigational new drug application became effective,463
E6-1313,,"6,090,382",Abbott Biotechnology Ltd,1722,1443,279,"April 16, 1998",,"December 31, 2002",the date the investigational new drug application became effective,326
06-903,ALOXI (palonosetron hydrochloride,"5,202,333","Roche Palo Alto, LLC, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",3867,3565,302,,,"July 25, 2003",the new drug application (NDA) for ALOXI (NDA 21-372),1827
E6-1365,OMACOR (omega-3-acid ethyl esters,"5,656,667","Pronova Biocare AS, and the Patent and Trademark Office requested FDA's assistance in determining these patents' eligibility for patent term restoration",3712,3408,304,,,"November 10, 2004",the new drug application (NDA) for OMACOR (NDA 21-654),
E6-1436,,"5,563,146","Wyeth, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",814,513,301,,,"April 24, 2003","the date the investigational device exemption (IDE) required under section 520(g) of the act (21 U.S.C. 
                    

      ( print page 5861)
    
                    360j(g)) for human tests to begin became effective February 1, 2001.
                

                    2. 
                    The date the application",557
E6-1434,,"4,937,078","Mezei Associates, Ltd",2262,1028,1234,,,"May 13, 2004",NADA 141-186,1590
E6-1642,ALIMTA (pemetrexed,"5,344,932",Eli Lilly and Co,4166,4038,128,"September 10, 1992",,"February 4, 2004",the date the investigational new drug application became effective,1784
E6-2354,,"6,217,866","Aventis Pharmaceuticals, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",3375,3192,183,"November 18, 1994",,"February 12, 2004",the date the investigational new drug application became effective,391
E6-3711,RELPAX (eletriptan hydrobromide,"5,545,644","Pfizer, Inc",2829,1307,1522,"March 31, 1995",,"December 26, 2002",the date the investigational new drug application became effective,1230
E6-3640,OVIDREL (choriogonadotropin alfa for injection,"4,840,896",Genzyme Corp,1787,1485,302,,,"September 20, 2000",NDA 21-149,1054
E6-3641,CRESTOR (rosuvastatin calcium,"RE37,314","Shionogi Seiyaku Kabushiki Kaisha, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",1831,1053,778,,,"August 12, 2003",the date the Investigational New Drug application (IND) became effective,1304
E6-3712,PRIALT (ziconotide,"5,795,864","Elan Pharmaceuticals, Inc",3801,1973,1828,"August 4, 1994",,"December 28, 2004",the date the investigational new drug application became effective,
E6-3781,,"5,840,299","Athena Neurosciences, Inc",2924,2740,184,"November 23, 1996",,"November 23, 2004",the date the investigational new drug application became effective,1189
E6-3956,MYCAMINE (micafungin sodium,"5,376,634","Astellas Pharma, Inc",2546,1493,1053,,"April 29, 2002","March 16, 2005",the new drug application (NDA) for MYCAMINE (NDA 21-506),1814
E6-4163,,"5,034,230",Santen Pharmaceutical Co,1298,1115,183,,,"September 24, 1999",NDA 21-079,755
E6-4165,MYCAMINE (micafungin sodium,"5,376,634","Astellas Pharma, Inc",2546,2221,325,,,"March 16, 2005",NDA 21-754,476
E6-4164,VESICARE (solifenacin succinate,"6,017,927",Yamanouchi Pharmaceutical Co,2027,1325,702,,,"November 19, 2004",the date the Investigational New Drug application became effective,329
E6-6083,,,,,,,"January 5, 1997",,,the date the investigational new drug application became effective,
E6-9031,CETROTIDE (cetrorelix acetate,"5,198,533","Administrators of the Tulane Educational Fund, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",2103,1815,288,,"October 29, 1999","August 11, 2000",NDA 21-197,1491
E6-9138,INCRELEX (mecasermin [rDNA origin] injection,"5,681,814","Genentech, Inc",4828,4644,184,,"February 28, 2005","August 30, 2005",the new drug application (NDA) for Increlex (NDA 21-839),1058
E6-9213,,"5,827,937","Q-Med AB, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",1491,949,542,,,"December 12, 2003",the premarket approval application (PMA) for RESTYLANE (PMA P020023),879
E6-9139,LUVERIS (lutropin alfa,"5,639,639",Genzyme Corp,3927,2670,1257,"January 9, 1994","May 1, 2001","October 8, 2004",the date the investigational new drug application became effective,1780
E6-9201,UROXATRAL (alfuzosin hydrochloride,"4,661,491","Sanofi-Synthelabo, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",2477,1560,917,,"December 8, 2000","June 12, 2003",the new drug application (NDA) for UROXATRAL (NDA 21-287),1481
E6-9214,TYGACIL (tigecycline,"5,529,990",Wyeth Holdings Corp,2487,2304,183,"August 26, 1998","December 15, 2004","June 15, 2005",the date the investigational new drug application became effective,1335
E6-9224,DUTASTERIDE (dutasteride,"5,565,467","GlaxoSmithKline, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",2373,2038,335,,"December 21, 2000","November 20, 2001",the new drug application (NDA) for DUTASTERIDE (NDA 21-319),769
E6-9225,CUBICIN (daptomycin,"4,885,243","Cubist Pharmaceuticals, Inc",6444,6177,267,,"December 20, 2002","September 12, 2003",the new drug application (NDA) for CUBICIN (NDA 21-572),1347
E6-9412,INSPRA (eplerenone,"4,559,332",Novartis Corp,349452135,1832,303,"November 24, 1996","November 29, 2001","September 27, 2002",the date the investigational new drug application became effective,1218
E6-9414,SYMLIN (pramlintide acetate,"5,686,411","Amylin Pharmaceuticals, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",4620,3060,1560,,"December 8, 2000","March 16, 2005",NDA 21-332,1586
E6-9509,ROZEREM (ramelteon,"6,034,239",Takeda Pharmaceutical Co,2224,1920,304,,"September 22, 2004","July 22, 2005",the new drug application (NDA) for Rozerem (NDA 21-782),808
E6-9817,BONIVA (ibandronate sodium,"4,927,814",Hoffmann-La Roche Inc,2559,2254,,"May 15, 1996","July 16, 2002","May 16, 2003",the date the investigational new drug application became effective,337
E6-9899,CIALIS (tadalafil,"5,859,006","ICOS Corporation, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",1943,1067,876,"July 29, 1998","June 29, 2001","November 21, 2003",the date the investigational new drug application became effective,679
E6-10408,,"5,716,981","Angiotech Phamaceuticals, Inc",716,456,260,,,"March 4, 2004",PMA P030025,807
E6-10796,MULTIHANCE (gadobenate dimeglumine,"4,916,246",Bracco International B,3789,2482,1307,"July 12, 1994",,,the date the investigational new drug application became effective,
E6-12574,CYMBALTA (duloxetine hydrochloride,"5,023,269","Eli Lilly and Company, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",4781,3786,995,"July 4, 1991","November 13, 2001","August 3, 2004",the date the investigational new drug application became effective,1826
E6-12571,IPLEX (mecasermin rinfabate [rDNA origin],"5,681,818",Insmed Inc,3527,3183,344,,"January 3, 2005","December 12, 2005",the new drug application (NDA) for IPLEX (NDA 21-884),1657
E6-12572,,"4,631,278",Janssen Pharmaceutica N,5111,1749,,,,"April 21, 1999",the date the investigational new animal drug application became effective,1096
E6-12573,EMEND (aprepitant,"5,719,147",Merck & Co,2513,2332,181,,"September 27, 2002","March 26, 2003",the new drug application (NDA) for EMEND (NDA 21-549),1022
E6-15554,,"6,133,418","Duke University, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",2312,2133,179,"November 14, 1996","September 16, 2002","March 13, 2003",the date the investigational new drug application became effective,569
E6-15555,,"6,054,297","Genentech, Inc",2551,2401,150,,,"February 26, 2004",BLA 125085/0,307
E6-15556,,"6,051,698","Gilead Sciences, Inc",2312,2128,184,,,"December 17, 2004",NDA 21-756,990
E6-15553,,"5,852,195",Pharmacia & Upjohn Co,3114,2931,183,,"December 22, 2004","June 22, 2005",NDA 21-814,1278
06-7800,,"4,916,154","American Cyanamid Company, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",2857,2841,16,,,"January 28, 1998",NADA 141-099,1754
06-7985,MYCAMINE (mycafungin sodium,,"Astellas Pharma, Inc",2546,2221,325,,"April 26, 2004","March 16, 2005",NDA 21-754,
06-8115,CLOLAR (clofarabine,"5,661,136","Southern Research Institute, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",2200,1926,274,,"March 30, 2004","December 28, 2004",NDA 21-673,1303
E6-15690,KETEK (telithromycin,"5,635,485",Aventis S,2206,713,1493,,"March 1, 2000","April 1, 2004",NDA 21-144,1076
E6-15767,MYCAMINE (micafungin sodium,,"Astellas Pharma, Inc",2546,1493,1053,,"April 29, 2002","March 16, 2005",the new drug application (NDA) for MYCAMINE (NDA 21-506),
E6-15908,LYRICA (NDA 21-446,"6,197,819","Warner-Lambert Company LLC, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",214463279,2852,427,,"October 31, 2003","December 30, 2004",NDA 21-446,299
E6-15969,PLENAXIS (abarelix,"5,843,901","Praecis Pharmaceuticals, Inc",2566,1487,1079,"November 17, 1996","December 12, 2000","November 25, 2003",the date the investigational new drug application became effective,725
E6-15987,TARCEVA (erlotinib,"5,747,498","Pfizer, Inc",2653,2541,112,,"July 30, 2004","November 18, 2004",NDA 21-743,1261
E6-15962,LYRICA (NDA 21-723,"6,001,876","Warner-Lambert Company LLC, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",217233279,2852,427,,"October 31, 2003","December 30, 2004",NDA 21-723,533
E6-16086,BYETTA (exenatide injection,"5,424,286","Amylin Pharmaceuticals, Inc",2271,1968,303,"February 10, 1999","June 30, 2004","April 28, 2005",the date the investigational new drug application became effective,1286
E6-16091,NATRECOR (nesiritide,"5,114,923","Scios, Inc",2790,1588,1202,,"April 27, 1998","August 10, 2001",the new drug application (NDA) for NATRECOR (NDA 20-920),
E6-16087,,"6,420,536","Pfizer, Inc",2451,2414,37,,,"May 24, 2005",the date the investigational new animal drug application (INADA) became effective,360
E6-16816,BONIVA (ibandronate sodium,"4,927,814","Hoffmann-La Roche, Inc",,2817,305,,"July 16, 2002","May 16, 2003",the date the IND became effective,1713
E7-2805,TYGACIL (tigecycline,"5,494,903",Wyeth Holdings Corp,2487,2304,183,"August 26, 1998","December 15, 2004","June 15, 2005",the date the investigational new drug application became effective,1335
E7-3001,LEVEMIR (insulin determir (rDNA origin,"5,750,497","Novo Nordisk A/S, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",2896,1971,925,"July 14, 1997","December 5, 2002","June 16, 2005",the date the investigational new drug application became effective,
E7-3041,EXJADE (deferasirox,"6,465,504","Novartis AG, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",2288,2103,185,"July 31, 1999","May 2, 2005","November 2, 2005",the date the investigational new drug application became effective,648
E7-3042,BARACLUDE (entecavir,"5,206,244",Bristol-Myers Squibb Co,2993,2811,182,"January 19, 1997","September 29, 2004","March 29, 2005",the new drug application (NDA) for BARACLUDE (NDA 21-797),1587
E7-3128,AMITIZA (lubiprostone,"5,284,858","Sucampo AG, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",2197,1890,307,,"March 31, 2005","January 31, 2006",the new drug application (NDA) for AMITIZA (NDA 21-908),1251
E7-3127,,,"Medtronic Vascular, and the Patent and Trademark Office requested FDA's assistance in determining the patents' eligibilities for patent term restoration",8652,477,175,,,"October 1, 2003","the date the investigational device exemption (IDE) required under section 520(g) of the act for human tests to begin became effective December 20, 2001.
                

                    2. 
                    The date the application",
E7-5439,REVLIMID (lenalidomide,"5,635,517",Celgene Corp,2069,1804,265,,"April 7, 2005","December 27, 2005",the new drug application (NDA) for REVLIMID (NDA 21-880),1166
E7-5443,,"5,981,576",Merck Frosst Canada & Co,2216,2118,98,,,"July 21, 2004",the date the investigational new animal drug application (INAD) became effective,650
E7-5445,NOVOLOG (insulin aspart (rDNA origin,"5,618,913","Novo Nordisk A/S, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",1776,1145,631,"July 30, 1995","September 16, 1998","June 7, 2000",the date the investigational new drug application became effective,59
E7-5446,EMTRIVA (emtricitabine,"5,914,331","Emory University, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",2114,1811,303,,"September 3, 2002","July 2, 2003",the new drug application (NDA) for EMTRIVA (NDA 21-500),642
E7-5444,,"5,667,767","Micro Therapeutics, Inc",1682,825,857,,,"July 21, 2005","the date the investigational device exemption (IDE) required under section 520(g) of the act for human tests to begin became effective December 14, 2000.
                

                    2. 
                    The date the application",1271
E7-5504,,"4,861,779","Pfizer, Inc",1805365,5314,51,,,,the new animal drug Application (NADA) for A180 (NADA 141-207),1826
E7-5635,,,"SDGI Holdings, Inc",2052,1515,537,,,"July 2, 2002","the date the investigational device exemption (IDE) required under section 520(g) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 360j(g)) for human tests to begin became effective November 20, 1996.
                

                    2. 
                    The date the application",
E7-5737,VAPRISOL (conivaptan hydrochloride,"5,723,606","Astellas Pharma, Inc",2796,2096,700,,"January 30, 2004","December 29, 2005",the date the Investigational New Drug application became effective,1745
E7-5736,,"5,223,256","Boehringer Mannheim GmbH, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",1919,1430,489,,,"October 30, 1996",the product license application (PLA) for Retevase (PLA 95-1167),123
E7-6053,,"5,677,278",Chiron Corp,3303,3119,184,"December 2, 1995",,"December 15, 2004",the date the investigational new drug application became effective,1417
E7-6061,RANEXA (ranolazine,"4,567,264","Roche Palo Alto, L",6770,5645,1125,,"December 30, 2002","January 27, 2006",the new drug application (NDA) for RANEXA (NDA 21-526),
E7-9730,NOXAFIL (posaconazole,"5,661,151",Schering Corp,3650,3382,268,,"December 22, 2005","September 15, 2006",NDA 22-003,1789
E7-9733,IRESSA (gefitinib,"5,770,599","AstraZeneca UK Limited, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",1967,1693,274,"December 17, 1997","August 5, 2002","May 5, 2003",the date the investigational new drug application became effective,374
E7-9720,,"5,199,939",Guidant Corp,1523,1203,320,,,"November 2, 2001","the date the investigational device exemption (IDE) required under section 520(g) of the act for human tests to begin became effective September 3, 1997.
                

                    2. 
                    The date the application",1062
E7-9787,FOSRENOL (lanthanum carbonate hydrate,"5,968,976","Shire International Licensing, B",2449,1538,911,"February 13, 1998","April 30, 2002","October 26, 2004",the date the investigational new drug application became effective,951
E7-9945,,"5,851,795","Bristol-Myers Squibb Company, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",3803,3536,267,"July 28, 1995",,"December 23, 2005",the date the investigational new drug application became effective,1414
E7-9951,,"5,932,211","Women's and Children's Hospital, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",2008,1764,244,,,"July 24, 2006",the biologics license application (BLA) for ELAPRASE (BLA 125151),1103
E7-9957,BEXTRA (valdecoxib,"5,633,272",G,1767,1462,305,,"January 16, 2001","November 16, 2001",the new drug application (NDA) for Bextra (NDA 21-341),276
E7-9950,,"5,820,870",Merck & Co,2215,2031,184,,,"June 8, 2006",the product license application (BLA) for GARDASIL (BLA 125126/0),1200
E7-10052,SOMAVERT (pegvisomant,"5,849,535","Genentech, Inc",2169,1349,820,"April 18, 1997","December 26, 2000","March 25, 2003",the date the investigational new drug application became effective,466
E7-10087,,"6,118,045",Genzyme Corp,1225,950,275,,,"April 28, 2006",BLA 125141/0,1251
E7-10147,PREZISTA (darunavir ethanolate,"6,248,775",G,1253,1070,183,,"December 23, 2005","June 23, 2006",the new drug application (NDA) for PREZISTA (NDA 21-976),717
E7-10127,,"4,958,632","Medtronic, Inc",401403716,358,358,,,"January 30, 1998",PMA 970012,358
E7-10089,SPRYCEL—NDAs 21-986 and 22-072 (dasatinib,"6,596,746","Bristol-Myers Squibb Company, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",21986220721183,1000,183,,"December 28, 2005",,,76
E7-10602,,"4,900,735",Intervet International B,4720,4674,46,,,"August 10, 2006",the date the investigational new animal drug application (INAD) became effective,
E7-10632,,"5,101,013","Hoechst Aktiengesellschaft, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",1591,1227,364,"December 14, 1995","April 23, 1999","April 20, 2000",the date the investigational new drug application became effective,976
E7-10631,,"5,192,319","Ophtec USA, Inc",2545,2107,438,,,"September 10, 2004","the date the investigational device exemption (IDE) required under section 520(g) of the act for human tests to begin became effective September 24, 1997.
                

                    2. 
                    The date the application",1484
E7-10633,,"5,124,316","Biomimetic Therapeutics, Inc",211361,744,617,,,"November 18, 2005","the date the investigational device exemption (IDE) required under section 520(g) of the act for human tests to begin became effective February 28, 2002.
                

                    2. 
                    The date the application",987
E7-10618,,"6,235,030",St,2224,1538,686,,,"November 21, 2005",the premarket approval application (PMA) for X-STOP INTERSPINOUS PROCESS DECOMPRESSION SYSTEM (PMA P040001),1053
E7-10730,", NAMENDA 
                    

      ( print page 31076",,"Forest Laboratories, Inc",5001,4699,302,,"December 19, 2002","October 16, 2003",the new drug application (NDA) (NDA 21-487),1250
E7-10853,RAPLON (Rapacuronium Bromide,"5,418,226",Akzo Nobel N,1724,1304,420,,"June 25, 1998","August 18, 1999",the new drug application (NDA) for RAPLON (NDA 20-984),126
E7-10915,CHANTIX (varenicline tartrate,"6,410,550","Pfizer, Inc",2401,2219,182,,"November 10, 2005","May 10, 2006",the new drug application (NDA) for CHANTIX (NDA 21-928),545
E8-6851,,"5,470,932","Alcon Manufacturing, Ltd",1084,538,546,,,"June 24, 2003",PMA P930014/S009,832
E8-9592,,"5,344,452","Artes Medical USA, Inc",3530,1859,1671,,,"October 27, 2006","the date the investigational device exemption (IDE) required under section 520(g) of the act for human tests to begin became effective February 28, 1997.
                

                    2. 
                    The date an application",1827
E8-9591,,"5,453,446","Teva Pharmaceutical Industries, Ltd",4269,3284,985,,"September 5, 2003","May 16, 2006",the new drug application (NDA) for Azilect (NDA 21-641),1827
E8-9699,TEKTURNA (aliskiren hemifumarate,"5,559,111","Novartis Corporation, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",2023,1637,386,"August 22, 2001",,"March 5, 2007",the date the investigational new drug application became effective,2022
E8-10466,,"5,482,934","Altana Pharma AG, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",3196,2893,303,"January 21, 1998","December 22, 2005","October 20, 2006",the date the investigational new drug application became effective,1748
E8-10512,,"6,235,883",Amgen Fremont Inc,2662,2479,183,,,"September 27, 2006",BLA 125147/0,1122
E8-10685,INVEGA (paliperidone,"5,158,952","Janssen, L",1406,1021,385,,"November 30, 2005","December 19, 2006",the new drug application (NDA) for INVEGA (NDA 21-999),896
E8-10689,ZOLINZA (vorinostat,RE38506 E,"Sloan-Kettering Institute for Cancer Research, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",2449,2266,183,,"April 7, 2006","October 6, 2006",NDA 21-991,1433
E8-10726,,"6,639,055","Genentech, Inc",2551,2401,150,,,"February 26, 2004",BLA 125085/0,121
E8-10857,,,"Idenix Pharmaceuticals, Inc",2309,2009,300,,,"October 25, 2006",the new drug application (NDA) for TYZEKA (NDA 22-011),442
E8-12007,,,"Genentech, Inc",2430,2247,183,,,"June 30, 2006",BLA 125156/0,
E8-12296,,,Mitsui Norin Co,3002,2605,397,,"September 30, 2005","October 31, 2006",NDA 21-902,1300
E8-12300,,,,,,,,,,,
E8-13109,,"5,626,851","the Wistar Institute of Anatomy and Biology and the Children's Hospital of Philadelphia, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",4577,4272,305,,,"February 3, 2006",,
E8-14156,", ERAXIS (anidulafungin","5,965,525",Eli Lilly and Co,3476,2446,1030,,"April 25, 2003","February 17, 2006",NDA 21-948,1224
E8-26679,TYKERB (lapatinib,"6,713,485",SmithKline Beecham Corp,2260,2078,182,"January 5, 2001","September 13, 2006","March 13, 2007",the date the investigational new drug application became effective,628
E8-26678,IXEMPRA (ixabepilone,"6,605,599",Bristol Myers Squibb Co,3002,2818,184,,"April 16, 2007","October 16, 2007",the new drug application (NDA) for Ixempra (NDA 22-065),854
E8-27179,SOMATULINE DEPOT (lanreotide,"5,595,760","Society De Conseils De Recherches Et D'Applications Scientifiques, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",3629,3324,305,"September 24, 1997","October 30, 2006","August 30, 2007",the date the investigational new drug application became effective,
E9-2683,LETAIRIS (ambrisentan,,Abbott Gmbh & Co,1871,1691,180,,"December 18, 2006","June 15, 2007",the new drug application (NDA) for LETAIRIS (NDA 22-081),
E9-2681,", LUNESTA (eszopiclone","6,444,673","Sepracor, Inc",1941,1256,685,,"January 31, 2003","December 15, 2004",NDA 21-476,760
E9-2812,,"6,583,272",Hoffmann-La Roche Inc,2140,1565,575,,,"November 14, 2007",BLA B125164/0,
E9-2813,SELZENTRY (maraviroc,"6,667,314",Pfizer Inc,1524,1294,230,,"December 20, 2006","August 6, 2007",NDA 22-128,73
E9-2684,,"5,364,646",Dr,2751,2715,36,,,"April 30, 2007",the new animal drug application (NADA) for VETMEDIN (NADA 141-273),1492
E9-2903,,,"Uroplasty, Inc",2651,1973,678,,,"October 30, 2006",PMA P040050,1640
E9-4374,,"5,624,411","Medtronic, Inc",1507,1068,439,,,"February 1, 2008",the date the investigational device exemption (IDE) required under section 520(g) of the act for human tests to begin became effective,954
E9-4526,,"6,355,245","Alexion Pharmaceuticals, Inc",1360,1177,183,"June 27, 2003",,"March 16, 2007",the date the investigational new drug application became effective,735
E9-4770,ARRANON (nelarabine,"5,424,295",",SmithKline Beecham Corp",4163,3980,183,"June 7, 1994","April 29, 2005","October 28, 2005",the date the investigational new drug application became effective,
E9-4914,ALTABAX OINTMENT (retapamulin,"RE39,128E",SmithKline Beecham P,1602,1297,305,"November 24, 2002","June 12, 2006","April 12, 2007",the date the investigational new drug application became effective,833
E9-5109,,"6,255,320",Pfizer Inc,1887,1841,46,,,"January 29, 2007",NADA 141-262,267
E9-5112,,"6,222,038",Pfizer Inc,1887,1841,46,,,"January 29, 2007",NADA 141-263,1078
E9-5374,,"5,514,773",Astellas Pharma Inc,1585,1542,43,,,"June 29, 2007",NADA 141-275,1314
E9-10818,NEUPRO TRANSDERMAL SYSTEM (rotigotine,"6,884,434","Schwarz Pharma Limited, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",4367,3535,832,"May 27, 1995","January 28, 2005","May 9, 2007",the date the investigational new drug application became effective,744
E9-11219,SENSIPAR (cinacalcet hydrochloride,,"NPS Pharmaceuticals, Inc",2089,1906,183,,"September 8, 2003","March 8, 2004",NDA 21-688,
E9-12050,INTELENCE (etravirine,"7,037,917","Janssen Pharmaceutica, N",2235,2050,185,,"July 18, 2007","January 18, 2008",the new drug application (NDA) for INTELENCE (NDA 22-187),404
E9-18034,DUREZOL (difluprednate ophthalmic emulsion,"6,114,319",Senju Pharmaceutical Co,560,369,181,,,"June 23, 2008","the investigational new drug application became effective on December 13, 2006.
                

                    2. 
                    The date the application",369
E9-18032,RAPAFLO (silodosin,"5,387,603",Kissei Pharmaceutical Co,3681,3380,301,,"December 13, 2007","October 8, 2008",the new drug application (NDA) for RAPAFLO (NDA 22-206),1826
E9-18527,EOVIST (gadoxetate disodium,"6,039,931","Bayer Schering Pharma Aktiengesellschaft, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",3818,3450,368,,"July 2, 2007","July 3, 2008",NDA 22-090,1699
E9-18528,,,"ZymoGenetics, Inc",1511,1115,396,"November 30, 2003",,"January 17, 2008",,952
E9-18530,,"5,451,233","Abbott Cardiovascular Systems, Inc",1157,759,398,,,"July 2, 2008","the date the investigational device exemption (IDE) required under section 520(g) of the act for human tests to begin became effective on May 4, 2005.
                

                    2. 
                    The date an application",937
E9-19233,,"6,835,809",Amgen Inc,2319,2014,305,,,"August 22, 2008",the biologics license application (BLA) for NPLATE (BLA 125268/0),818
E9-20307,LEXISCAN (regadenoson monohydrate,,"CV Therapeutics, Inc",2446,2113,333,,"May 14, 2007","April 10, 2008",the new drug application (NDA) 22-161,
E9-21100,TAPENTADOL HYDROCHLORIDE (tapentadol hydrochloride,"RE 39,593","Grunenthal GmbH, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",2880,2577,303,"January 3, 2001","January 23, 2008","November 20, 2008",the date the investigational new drug application became effective,1492
E9-21428,BANZEL (rufinamide,"6,740,669","Novartis AG, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",6595,5501,1094,"October 27, 1990","November 17, 2005","November 14, 2008",the date the investigational new drug application became effective,819
E9-21365,DORIBAX (doripenem monohydrate,"5,317,016","Shionogi Seiyaku Kabushiki Kaisha, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",1746,1442,304,"January 2, 2003","December 13, 2006","October 12, 2007",the date the investigational new drug application became effective,1025
E9-21424,,"6,306,141","Medtronic, Inc",4024,3843,181,,,"April 15, 2008","the date the investigational device exemption (IDE) required under section 
                    

      ( print page 45866)
    
                    520(g) of the act for human tests to begin became effective April 11, 1997.
                

                    2. 
                    The date an application",1183
E9-23650,CLEVIPREX (clevidipine butyrate,,"AstraZeneca AB, and the Patent and Trademark Office requested FDA's assistance in determining the patents' eligibilities for patent term restoration",4475,4078,397,"May 3, 1996",,"August 1, 2008",the date the investigational new drug application became effective,1314
E9-23900,EMEND FOR INJECTION (fosaprepitant meglumine,"5,691,336",Merck & Co,4473,3810,663,,"April 3, 2006","January 25, 2008",NDA 22-023,1826
E9-24457,ENTEREG (alvimopan,,"Eli Lilly and Company, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",5305,3879,1426,,"June 25, 2004","May 20, 2008",the new drug application (NDA) 21-775,
2010-4159,FIRMAGON (degarelix acetate,"5,925,730","Ferring BV, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",2695,2394,301,"August 10, 2001","February 28, 2008","December 24, 2008",the date the investigational new drug application became effective,1498
2010-7516,LUSEDRA (fospropofol disodium,,"University of Kansas, and the Patent and Trademark Office requested FDA's assistance in determining the patents' eligibility for patent term restoration",2405,1962,443,"May 15, 2002","September 27, 2007","December 12, 2008",the date the investigational new drug application became effective,
2010-7678,FANAPT (iloperidone,"RE39,198",Aventis Holdings Inc,6552,5964,588,"May 31, 1991","September 27, 2007","May 6, 2009",the date the investigational new drug application became effective,
2010-7679,TOVIAZ (fesoterodine fumarate,"6,858,650","Schwarz Pharma AG, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",2395,1445,950,"April 13, 2002","March 27, 2006","October 31, 2008",the date the investigational new drug application became effective,1155
2010-8172,MOZOBIL (plerixafor,"5,583,131",Genzyme Corp,3849,3666,183,,"June 16, 2008","December 15, 2008",the new drug application (NDA) 22-311,1826
2010-8443,AFINITOR (everolimus,"5,665,772","Novartis AG, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",4486,4212,274,"December 19, 1996","June 30, 2008","March 30, 2009",the date the investigational new drug application became effective,1826
2010-8518,SAVELLA (milnacipran hydrochloride,,"Cypress Bioscience, Inc",2571,2177,394,"January 2, 2002","December 18, 2007","January 14, 2009",the date the investigational new drug application became effective,
2010-9509,VIMPAT (lacosamide,,"Research Corporation Technologies, Inc",3452,3055,397,,,"October 28, 2008",the new drug application (NDA) 22-254 for VIMPAT injection,
2010-9512,", VIMPAT (lacosamide",,"Research Corporation Technologies, Inc",3452,3055,397,"May 19, 1999","September 28, 2007","October 28, 2008",the date the investigational new drug application became effective,1827
2010-13655,ABLAVAR (gadofosveset trisodium,,"Epix Pharmaceuticals, Inc",4508,2673,1835,"August 21, 1996","December 15, 2003","December 22, 2008",the date the investigational new drug application became effective,
2010-13905,PROMACTA (eltrombopag olamine,"7,160,870",SmithKline Beecham Corp,1485,1147,338,,"December 19, 2007","November 20, 2008",the new drug application (NDA) 22-291,347
2010-14814,BYSTOLIC (nebivolol hydrochloride,,"Forest Laboratories, Inc",6790,5463,,,,"December 17, 2007",NDA 21-742,
2010-21586,PRISTIQ (desvenlafaxine sucinate,,"Wyeth, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",2124,1324,800,"May 9, 2002","December 22, 2005","February 29, 2008",the date the investigational new drug application became effective,
2010-21583,ONGLYZA (saxagliptin,"6,395,767",Bristol-Myers Squibb Co,2794,2397,397,,"June 30, 2008","July 31, 2009",the new drug application (NDA) for ONGLYZA (NDA 22-350),896
C1-2010-21583,,,,,,,,,,,
C1-2010-21586,,,,,,,,,,,
2010-22081,,"5,472,438","Case Western Reserve University, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",5166,4830,336,,,"June 17, 2008","the date the investigational device exemption (IDE) required under section 520(g) of the act for human tests to begin became effective April 28, 1994.
2. The date an application",1737
2010-22234,EFFIENT (Prasugrel Hydrochloride,"5,288,726",Daiichi Sankyo Co,2795,2232,563,"November 16, 2001","December 26, 2007","July 10, 2009",the date the investigational new drug application became effective,1679
2010-22177,,"6,156,067","Medtronic Sofamor Danek, Inc",2702,1653,1049,,,"May 12, 2009","the date the investigational device exemption (IDE) required under section 520(g) of the act for human tests to begin became effective December 20, 2001.
                

                    2. 
                    The date an application",1826
2010-22394,,"6,309,650",Chiel Jedang Corp,3461,2994,467,,,"March 30, 2009",the biologics license application (BLA) for IXIARO (BLA B125280/0),1588
2010-22496,,"5,711,958","SyntheMed, Inc",4023,3256,767,,,"March 6, 2009","the date the investigational device exemption (IDE) required under section 520(g) of the act for human tests to begin became effective March 3, 1998.
                

                    2. 
                    The date an application",1742
2010-22519,SAPHRIS (asenapine,"5,763,476","NV Organon, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",4547,3833,714,"March 4, 1997","August 31, 2007","August 13, 2009",the date the investigational new drug application became effective,1827
2010-22521,ULORIC (febuxostat,"5,614,520",Teijin Pharma Ltd,3395,1873,1522,,"December 15, 2004","February 13, 2009",NDA 21-856,
2010-30512,,"6,902,734 and 7,166,285",Centocor Ortho Biotech Inc,3165,2498,667,,,"September 25, 2009","the biologics license application (BLA) for 
                    STELARA
                     (BLA 125261/0)",
2010-30510,"BESIVANCE
                     (besifloxacin hydrochloride","5,447,926",Bausch & Lomb Inc,2271,1910,361,"March 12, 2003",,"May 28, 2009",the date the investigational new drug application became effective,1316
2010-30992,,"7,446,175","Novartis AG, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",1072,889,183,,,"June 17, 2009",BLA 125319,177
2010-30991,BEPREVE (bepotastine besilate,"6,780,877","Ube Industries, Ltd",964,663,301,,,"September 8, 2009",the new drug application (NDA) 22-288,631
2010-30995,SABRIL (vigabatrin,"5,380,936","Lundbeck, Inc",10205,4614,5591,"September 14, 1981",,,the date the investigational new drug application became effective,
2010-31074,COARTEM (artemether/lumefantrine,"5,677,331","Novartis AG, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",285,,285,,,"April 7, 2009",the new drug application (NDA) 22-268,284
2010-31064,MULTAQ (dronedarone hydrochloride,,"Sanofi-Aventis, and the Patent and Trademark Office requested FDA's assistance in determining the patents' eligibility for patent term restoration",5076,3593,1483,"August 10, 1995",,"July 1, 2009",the date the investigational new drug application became effective,
2010-31250,VIBATIV (televancin hydrochloride,,"Theravance, Inc",2635,1637,998,"June 27, 2002",,"September 11, 2009",the date the investigational new drug application became effective,
2010-31298,SAMSCA (tolvaptan,,Otsuka Pharmaceutical Co,4722,4147,575,,,"May 19, 2009",the new drug application (NDA) for SAMSCA (NDA 22-275),
2010-31240,,"5,262,035",Abbott Diabetes Care Inc,2320,750,1570,,,"March 12, 2008","the device did not require an IDE under section 520(g) of the FD&C act, but did require IRB approval, granted November 6, 2001, for human tests to begin. This date represents the beginning of the testing phase of the regulatory review period.
                

                    2. 
                    The date an application",1826
2010-31583,,"5,196,404","The Medicines Company, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",3665,2576,1089,,,"December 15, 2000",the new drug application (NDA) for ANGIOMAX (NDA 20-873),1773
2010-31846,FOLOTYN (pralatrexate,"6,028,071","Southern Research Institute, Sloan-Kettering Institute for Cancer Research, and SRI International, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",4591,4406,185,,,"September 24, 2009",NDA 22-468,1826
2010-31847,LIVALO (pitavastatin calcium,"5,856,336","Nissan Chemical Industries, Ltd",3341,3036,305,,,"August 3, 2009",NDA 22-363,1826
2011-5312,AMPYRA (dalfampridine,,Elan Pharma International Ltd,9845,9569,276,,,"January 22, 2010",the new drug application (NDA) for AMPYRA (NDA 22-250),
2011-5310,,"7,351,533","MedImmune, LLC",4027,3094,933,,,"October 16, 2009",the biologics license application (BLA) for CERVARIX (BLA 125259/0),562
2011-6162,ISTODAX (romidepsin,"4,977,138","Gloucester Pharmaceuticals, Inc",2717,2419,298,,,"November 5, 2009",the new drug application (NDA) for ISTODAX (NDA 22-393),1523
2011-6514,VPRIV (velaglucerase alfa,"7,138,262","Shire Human Genetic Therapies, Inc",2221,2041,180,,,"February 26, 2010",the new drug application (NDA) for VPRIV (NDA 22-575),687
2011-6509,,"6,441,145","GTC Biotherapeutics, Inc",4468,4285,183,,,"February 6, 2009",BLA 125284,1243
2011-9153,,,,,,,,,,,
2011-10379,,"6,020,329","Pfizer, Inc",2841,2801,40,,,"April 25, 2008",NADA 141-285,1462
2011-10870,VOTRIENT (pazopanib hydrochloride,"7,105,530","GlaxoSmithKline, LLC",2568,2263,305,,,"October 19, 2009",the new drug application (NDA) for Votrient (NDA 22-465),719
2011-11903,,,,,,,,,,,
2011-13388,,,,1893,1111,782,"November 4, 2004",,"January 8, 2010",the date the investigational new drug application became effective,1338
2011-15197,,"6,306,900","Novartis AG, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration and that FDA determine the product's regulatory review period",1947,1643,304,"October 31, 1998",,"February 27, 2004",the date the investigational new drug application became effective,323
2011-15625,,"6,034,267","PhotoCure ASA, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration and that FDA determine the product's regulatory review period",1695,659,1036,,,"July 27, 2004",the new drug application (NDA) for METVIXIA (NDA 21-415),871
2011-15691,BROVANA (arformoterol tartrate,"6,589,508",Sepracor Inc,3118,2819,299,"March 26, 1998",,"October 6, 2006",the date the investigational new drug application became effective,745
2011-15692,DEXILANT (dexlansoprazole,,Takeda Pharmaceutical Co,1675,1278,397,"July 2, 2004",,"January 30, 2009",the date the investigational new drug application became effective,
2011-15689,Fusilev (levoleucovorin calcium,"6,500,829","the University of Strathclyde, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration and that FDA determine the product's regulatory review period",6993,703,6290,,,"March 7, 2008",NDA 20-140,797
2011-15910,XYZAL (levocetirizine dihydrochloride,"5,698,558",UCB Inc,305,0,305,,,"May 25, 2007",no investigational new drug application,245
2011-15905,INVEGA SUSTENNA (paliperidone palmitate,"5,254,556","Janssen, L",2253,1608,645,"June 2, 2003",,"July 31, 2009",the date the investigational new drug application became effective,1449
2012-8235,,"5,607,690",Altergon S,4031,1796,2235,"January 20, 1996",,"January 31, 2007",the date the investigational new drug application became effective,1825
2012-8341,VIIBRYD (vilazodone hydrochloride,,"Merck Patent GmbH, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",4778,4472,306,"December 24, 1997",,"January 21, 2011",the date the investigational new drug application became effective,
2012-8339,TEFLARO (ceftaroline fosamil,,"Takeda Pharmaceutical Company Limited, and the Patent and Trademark Office requested FDA's assistance in determining the patents' eligibility for patent term restoration",2118,1814,304,"January 12, 2005",,"October 29, 2010",the date the investigational new drug application became effective,
2012-8337,NATROBA (spinosad,,"Eli Lilly and Company, and the Patent and Trademark Office requested FDA's assistance in determining these patents' eligibility for patent term restoration",2261,1534,727,"November 11, 2004",,"January 18, 2011",the date the investigational new drug application became effective,
2012-8340,DATSCAN (Ioflupane I-123 injection,"5,310,912","GE Healthcare Limited, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",677,0,677,,,"January 14, 2011",NDA 22-454,
2012-8354,LATUDA (lurasidone hydrochloride,"5,532,372",Dainippon Sumitomo Pharma Co,3602,3299,303,,,"October 28, 2010",the new drug application (NDA) for LATUDA (NDA 200-603),1826
2012-9325,,,,,,,,,,,
2012-10518,,,Dyax Corp,2855,2420,435,"February 8, 2002",,"December 1, 2009",the date the investigational new drug application became effective,
2012-10517,VICTOZA (liraglutide (rDNA origin,"6,268,343","Novo Nordisk A/S, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",3370,2757,,,,"January 25, 2010",the new drug application (NDA) for Victoza (NDA 22-341),1826
2012-10516,,"6,411,852","Asthmatx, Inc",1743,1259,484,,,"April 27, 2010","the date the investigational device exemption (IDE) required under section 520(g) of the FD&C Act for human tests to begin became effective July 21, 2005.
                

                    2. 
                    The date an application",1114
2012-10716,HALAVEN (eribulin mesylate,"6,214,865",Eisai R&D Management Co,2758,2527,231,"April 30, 2003",,"November 15, 2010",the date the investigational new drug application became effective,1495
2012-10697,,( print page 26291,"Mountain View Pharmaceuticals, Inc",3193,2509,684,"December 19, 2001",,"September 14, 2010",the date the investigational new drug application became effective,1445
2012-10694,LASTACAFT (alcaftadine ophthalmic solution,"5,468,743",Janssen Pharmaceutica N,2189,1886,303,,,"July 28, 2010",NDA 22-134,1246
2012-10712,PRADAXA (dabigatran etexilate mesylate,"6,087,380",Boehringer Ingelheim Pharma GmbH & Co,2633,2449,184,,,"October 19, 2010",NDA 22-512,1469
2012-10819,GILENYA (fingolimod,"5,604,229",Novartis Pharmaceuticals Corp,4296,4021,275,,,"September 21, 2010",NDA 22-527,
2012-10808,EGRIFTA (tesamorelin acetate,"5,861,379","Theratechnologies, Inc",3284,2753,531,"November 15, 2001",,"November 10, 2010",the date the investigational new drug application became effective,1827
2012-10849,FERAHEME (ferumoxytol,"6,599,498","AMAG Pharmaceuticals, Inc",3680,3120,560,,,"June 30, 2009",NDA 22-180,1209
2012-10828,JEVTANA (cabazitaxel,,Aventis Pharma S,4250,4171,79,"October 30, 1998",,"June 17, 2010",the date the investigational new drug application became effective,
2012-10853,,"5,372,818","Dechra, Ltd",6378,6336,42,,,"September 9, 2010",NADA 141-314,
2012-10959,,,"Amgen, Inc",3269,2739,530,"June 21, 2001",,"June 1, 2010",the date the investigational new drug application became effective,
2012-13902,,,,,,,,,,,
2012-14003,CYSVIEW (hexaminolevulinate hydrochloride,,"Photocure ASA, and the Patent and Trademark Office requested FDA's assistance in determining the patents' eligibilities for patent term restoration",3103,2770,333,,,"May 28, 2010",the new drug application (NDA) for CYSVIEW (NDA 22-555),
2012-14000,,RE38158,"Neomend, Inc",3854,787,3067,,,"January 14, 2010","the date the investigational device exemption (IDE) required under section 520(g) of the FD&C Act for human tests to begin became effective June 29, 1999.
                

                    2. 
                    The date an application",
2012-21239,,"5,362,718","Wyeth, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration and that FDA determine the product's regulatory review period",3290,3052,238,"May 29, 1998",,"May 30, 2007",the date the investigational new drug application became effective,1764
2013-02085,XALKORI (crizotinib,"7,230,098",Pfizer Inc,2054,1904,150,,,"August 26, 2011",the new drug application (NDA) for XALKORI (NDA 202-570),178
2013-02086,"BEYAZ (drospirenone, ethinyl estradiol, and levomefolate calcium","6,441,168","Eprova AG, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",1271,874,397,"April 4, 2007",,"September 24, 2010",the date the investigational new drug application became effective,834
2013-04016,,"5,411,552",Edwards Lifesciences AG and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration,2473,2106,367,,,"November 2, 2011",PMA P100041,1757
2013-04645,ZYTIGA (abiraterone acetate,"5,604,213","BTG International LTD, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",1927,1797,130,,,"April 28, 2011",the new drug application (NDA) for ZYTIGA (NDA 202-379),1024
2013-04646,,"5,591,444","Fibrocell Technologies, Inc",3338,2500,838,"May 3, 2002",,"June 21, 2011",the date the investigational new drug application became effective,
2014-01307,GADAVIST (gadobutrol,"5,980,864",Bayer Schering Pharma Aktiengesellschaft and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration,4269,3964,305,"July 8, 1999",,"March 14, 2011",the date the investigational new drug application became effective,1470
2014-01306,DALIRESP (roflumilast,"5,712,298","Nycomed GmbH, and the U",4237,3645,592,,,"February 28, 2011",the new drug application (NDA) for DALIRESP (NDA 22-522),1826
2014-07060,,"7,094,874","Bristol-Myers Squibb Company, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",4479,3764,715,"March 13, 1999",,"June 15, 2011",the date the investigational new drug application became effective,
2014-07058,,"5,614,382",Wyeth Holdings Corp,132102,1771,331,,,"February 24, 2010",BLA 125324,1312
2014-07334,,"6,538,151","Valeant Pharmaceuticals North America, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",5021,4432,589,"September 12, 1997",,"June 10, 2011",the date the investigational new drug application became effective,1794
2014-07331,FIRAZYR (icatibant acetate,"5,648,333","Sanofi-Aventis Deutschland GmbH, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",2663,1263,1400,"May 12, 2004",,"August 25, 2011",the date the investigational new drug application became effective,
2014-07333,,,"Regeneron Pharmaceuticals, Inc",2349,2075,274,"June 15, 2005",,"November 18, 2011",the date the investigational new drug application became effective,
2014-07336,,,"Novartis Animal Health US, Inc",1704,1650,54,,,"March 8, 2011",NADA 141-320,
2014-07329,,"7,136,699","Novocure Limited, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",1001704,1468,236,,,"April 8, 2011","the date the investigational device exemption (IDE) required under section 520(g) of the FD&C Act for human tests to begin became effective August 10, 2006.
                

                    2. 
                    The date an application",807
2014-07657,,"6,208,749",MELA Sciences Inc,3837,2961,876,,,"November 1, 2011",the premarket approval application (PMA) for MELAFIND SYSTEM (PMA P090012),2355
2014-09772,,,"AstraZeneca UK Limited, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",2976,2364,612,"May 29, 2003",,"July 20, 2011",the date the investigational new drug application became effective,
2014-09910,,,"Medarex, Inc",3879,3605,274,"August 12, 2000",,"March 25, 2011",the date the investigational new drug application became effective,
2014-09911,,"7,125,879",Janssen Pharmaceutica N,2396,2094,302,"October 29, 2004",,"May 20, 2011",the date the investigational new drug application became effective,768
2014-10904,,"5,407,914","Discovery Laboratories, Inc",7124,4239,2885,"September 5, 1992",,"March 6, 2012",the date the investigational new drug application became effective,
2014-10945,,"7,407,955",Boehringer Ingelheim Pharma GmbH & Co,2051,1746,305,"September 21, 2005",,"May 2, 2011",the date the investigational new drug application became effective,629
2014-10951,,"7,534,441",Pfizer Inc,2555,2498,57,,,"March 22, 2011",NADA 141-322,366
2014-11175,,,"Onyx Therapeutics, Inc",2565,2267,298,"July 14, 2005",,"July 20, 2012",the date the investigational new drug application became effective,
2014-11176,,,Human Genome Sciences Inc,3426,3152,274,"October 23, 2001",,"March 9, 2011",the date the investigational new drug application became effective,
2014-11172,,"6,573,293","Sugen, Inc",2711,2681,30,,,"May 22, 2009",NADA 141-295,
2014-11516,,"7,951,557",Protalix Ltd,2483,1746,737,"July 16, 2005",,"May 1, 2012",the date the investigational new drug application became effective,336
2014-11517,,"5,886,035",Asahi Glass Company Ltd,3881,3481,400,,,"February 10, 2012",the new drug application (NDA) for ZIOPTAN (NDA 202514),
2014-11515,,,"Genentech, Inc",3925,3741,184,"September 11, 2001",,"June 8, 2012",the date the investigational new drug application became effective,
2014-11521,,"7,410,656",Leo Laboratories Ltd,2737,2432,305,,,"January 23, 2012",the new drug application (NDA) for Picato (NDA 202833),783
2014-11523,,"7,414,105","Affymax, Inc",2528,2222,306,"April 27, 2005",,"March 27, 2012",the date the investigational new drug application became effective,684
2014-11525,,"7,820,671","Vertex Pharmaceuticals Incorporated, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",2003,1821,182,,,"May 23, 2011",the new drug application (NDA) for INCIVEK (NDA 201-917),87
2014-11926,,"7,304,036","Ironwood Pharmaceuticals, Inc",2863,2475,388,"October 30, 2004",,"August 30, 2012",the date the investigational new drug application became effective,945
2014-11925,,"6,534,524","Agouron Pharmaceuticals, Inc",3699,3410,289,,,"January 27, 2012",the new drug application (NDA) for INLYTA (NDA 202324),1763
2014-12292,,,Astellas Pharma Inc,2213,1908,305,,,"June 28, 2012",the new drug application (NDA) for MYRBETRIQ (NDA 202611),
2014-12294,,,the Henry M,2924,1886,1038,,,"June 14, 2012",the biologics license application (BLA) for MENHIBRIX (BLA 125363),
2014-12279,,,"Seattle Genetics, Inc",1851,1678,173,,,"August 19, 2011",the date the investigational new drug application (IND) became effective,229
2014-12277,,,"Seattle Genetics, Inc",1851,1678,173,"July 27, 2006",,"August 19, 2011",the date the investigational new drug application became effective,1002
2014-12295,,"7,419,696","Medtronic, Inc",1586,1263,323,,,"February 17, 2012",the premarket approval application (PMA) for RESOLUTE INTEGRITY ZOTAROLIMUS-ELUTING CORONARY STENT SYSTEM (PMA P110013),794
2014-12349,,"7,157,456","Bayer Pharma Aktiengesellschaft, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",3291,2222,1069,,,"July 1, 2011",the new drug application (NDA) for XARELTO (NDA 22-406),1354
2014-12350,,"5,985,844",Merck Sharp & Dohme Corp,2990,2930,60,,,"June 16, 2011",NADA 141-328,1826
2014-12561,,"7,495,103",Vertex Pharmaceuticals Inc,2121,2015,106,"April 13, 2006",,"January 31, 2012",the date the investigational new drug application became effective,0
2014-12562,,"7,008,765","The Johns Hopkins University & The Stichting Katholieke Universiteit, The University Medical Centre Nijmegen, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",3936,383,553,,,"February 13, 2012",the premarket approval application (PMA) for PROGENSA PCA3 ASSAY (PMA 100033),745
2014-12808,,RE39941,"Auxilium Pharmaceuticals, Inc",5278,4937,341,"August 24, 1995",,"February 2, 2010",the date the investigational new drug application became effective,1806
2014-13444,,"6,656,935",Mitsubishi Tanabe Pharma Corp,3770,3466,304,"January 2, 2002",,"April 27, 2012",the date the investigational new drug application became effective,1686
2014-13445,,"5,514,154",Abbott Cardiovascular Systems Inc,890,694,196,,,"November 1, 2011","the date the investigational device exemption (IDE) required under section 520(g) of the FD&C Act for human tests to begin became effective May 27, 2009.
                

                    2. 
                    The date an application",630
2014-13566,,"7,173,038","AstraZeneca AB, and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration",4009,3735,274,,,"April 6, 2011",the new drug application (NDA) for VANDETANIB (NDA 22-405),898
2014-13567,,"RE42,353","AstraZeneca UK Limited, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",4009,3735,274,,,"April 6, 2011",the new drug application (NDA) for Vandetanib (NDA 22-405),1738
2014-13637,,"6,514,946","Koueki Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai, and USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",2903,2842,61,,,"May 14, 2012",NADA 141-334,1524
2014-13638,,"6,878,721","Novartis AG, and USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",3097,2171,926,"January 9, 2003",,"July 1, 2011",the date the investigational new drug application became effective,1597
2014-13640,,,"Medtronic CryoCath LP, and the Patent and Trademark Office requested FDA's assistance in determining the patents' eligibility for patent term restoration",2670,2389,281,,,"December 17, 2010",the date the investigational device exemption required under section 520(g) of the FD&C Act for human tests to begin became effective,
2014-15021,,RE43298,"Schering Corporation and Dendreon Corporation, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",2160,1980,180,,,"May 13, 2011",the new drug application (NDA) for VICTRELIS (NDA 202-258),1032
2014-16237,,"6,818,787","XenoPort, Inc",2277,1459,818,"January 12, 2005",,"April 6, 2011",the date the investigational new drug application became effective,882
2014-25032,,,"Durant Wayland, Inc",1950,,,,,,FAP 7M4768,
2015-07809,,"5,712,279","Aegerion Pharmaceuticals, Inc",6002,5705,297,"July 18, 1996",,"December 21, 2012",the date the investigational new drug application became effective,
2015-08362,,"7,176,220",Japan Tobacco Inc,2666,2360,306,,,"August 27, 2012",NDA 203-100,1021
2015-08615,,"5,679,709","sanofi-aventis Deutschland GMBH, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",2940,2542,398,"August 27, 2004",,"September 12, 2012",the date the investigational new drug application became effective,
2015-08616,,"6,794,410",Aventis Pharmaceuticals Inc,2940,2542,398,"August 27, 2004",,"September 12, 2012",the date the investigational new drug application became effective,1625
2015-08845,,"5,968,979","Hyperion Therapeutics, Inc",2126,1719,407,,,"February 1, 2013",the new drug application (NDA) for RAVICTI (NDA 203284),1450
2015-09302,,"7,579,473","Exelixis, Incorporated, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",2698,2513,185,"July 13, 2005",,"November 29, 2012",the date the investigational new drug application became effective,688
2015-09521,,"5,762,939","Protein Sciences Corporation, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",3010,1275,1735,,,"January 16, 2013",the biologics license application (BLA) for FLUBLOK (BLA 125285/0),
2015-09522,,"7,511,131","Genzyme Corporation, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",2601,2294,307,"December 18, 2005",,"January 29, 2013",the date the investigational new drug application became effective,853
2015-09902,,"7,828,766",Abbott Cardiovascular Systems Inc,178,0,178,,,"December 21, 2012",the PMA for Xience Xpedition Everolimus Eluting Coronary Stent System (PMA P110019S025),178
2015-10337,,"8,173,663",Takeda Pharmaceuticals U,3021,1164,1857,,,"January 25, 2013",the new drug application (NDA) for NESINA (NDA 22-271),264
2015-10333,,RE42376,"Wyeth Holdings Corporation, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",3032,2739,293,,,"September 4, 2012",the new drug application (NDA) for BOSULIF (NDA 203-341),1664
2015-10335,,"8,288,539","Takeda Pharmaceutical Company Limited, and the USPTO requested FDA's assistance in determining this 
                    

      ( print page 25303)
    
                    patent's eligibility for patent term restoration",1365,934,431,,,"January 25, 2013",the new drug application (NDA) for KAZANO (NDA 203-414),102
2015-10336,,,"Almiral, S",3136,2739,397,"December 24, 2003",,"July 23, 2012",the date the investigational new drug application became effective,
2015-10334,,,Cameron Health Inc,1024,743,281,,,"September 28, 2012","the date the investigational device exemption (IDE) required under section 520(g) of the FD&C act for human tests to begin became effective December 11, 2009.
                

                    2. 
                    The date an application",
2015-10338,,"8,062,345 B2",Bolton Medical Inc,2852,2529,323,,,"September 21, 2012",the premarket approval application (PMA) for the RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM (PMA P110038),225
2015-11004,,"6,987,103","Robin, Mahon, Maisonneuve, Maloisel, and Blanchard, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",4182,3037,1145,,,"October 26, 2012",the NDA for SYNRIBO,1217
2015-11000,,,"NPS Pharmaceuticals, Inc",262734959,4571,388,"May 27, 1999",,"December 21, 2012",the date the investigational new drug application became effective,
2015-10994,,"7,473,761","Novartis AG, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",3440,3138,302,,,"December 14, 2012",the new drug application (NDA) for SIGNIFOR (NDA 200677),503
2015-11002,,"6,329,404","Takeda Pharmaceutical Company Limited, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",2482,895,1587,,,"January 25, 2013",the new drug application (NDA) for OSENI (NDA 22-426),1826
2015-11003,,,"Penn State Research Foundation and Massachusetts Institute of Technology, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",3692,3644,48,,,"September 18, 2012",NADA 141-339,
2015-10998,,"5,645,599","Paradigm Spine, LLC, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",2382,1787,595,,,"October 17, 2012",PMA P110008,1503
2015-11001,,"6,234,772","HeartWare, Inc",1667,973,694,,,"November 20, 2012","the date the investigational device exemption required under section 520(g) of the FD&C act for human tests to begin became effective April 30, 2008.
                

                    2. 
                    The date an application",818
2015-10999,,"6,626,858","Glaukos Corporation, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",2820,1535,1285,,,"June 25, 2012","the date the investigational device exemption (IDE) required under section 520(g) of the FD&C Act for human tests to begin became effective October 7, 2004.
                

                    2. 
                    The date an application",
2015-12577,,"7,351,834","Bayer HealthCare LLC, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",2234,2080,154,"August 18, 2006",,"September 27, 2012",the date the investigational new drug application became effective,898
2015-12397,,"6,656,720","Novartis AG, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",2589,2224,365,,,"November 20, 2012",BLA 125408,1773
2015-14433,,"RE41,783",Pfizer Inc,3947,3564,383,"January 18, 2002",,"November 6, 2012",the date the investigational new drug application became effective,
2015-31098,,"7,498,343","Janssen Pharmaceutica, N",2213,2030,183,,,"December 28, 2012",the new drug application (NDA) for SIRTURO (NDA 204384),741
2015-31096,,"6,967,208","Bristol-Myers Squibb Company, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",3685,3227,458,"November 28, 2002",,"December 28, 2012",the date the investigational new drug application became effective,1424
2015-31099,,"6,323,213","Bayer Animal Health GmbH, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",3285,3235,50,,,"November 7, 2012",the new animal drug Application (NADA) for VERAFLOX (NADA 141-344),1901
2015-31097,,"7,323,195","Napo Pharmaceuticals, Inc",7784,7391,393,,,"December 31, 2012",NDA 202292,
2015-31095,,"7,668,599","Second Sight Medical Products, Inc",2282,1630,652,,,"February 14, 2013",,1735
2015-31401,,"7,270,800","GE Healthcare Limited, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",1541,1176,365,,,"October 25, 2013",the date the investigational new drug application (IND) became effective,951
2015-31400,,"7,906,119","Human Genome Sciences, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",3465,2154,1311,,,"December 14, 2012",BLA 125349/0,412
2015-31397,,"6,395,019","TriVascular, Inc",776403607,3429,178,,,"October 5, 2012",the premarket approval application (PMA) for TRIVASCULAR OVATION ABDOMINAL STENT GRAFT SYSTEM (PMA P120006),1802
2015-31824,,"8,183,274","The Regents of the University of California, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",1892,1790,102,"June 29, 2007",,"August 31, 2012",the date the investigational new drug application became effective,101
2015-32247,,,"ThromboGenics NV, and the USPTO requested FDA's assistance in determining these patents' eligibility for patent term restoration",2171,1987,184,,,"October 17, 2012",the biologics license application (BLA) for JETREA (BLA 125422/0),
2015-32475,,,"Genentech, Inc",2594,2414,180,"January 18, 2006",,"February 22, 2013",the date the investigational new drug application became effective,
2016-03551,,"7,439,393","Glaxo Group Limited, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",1980,1677,303,,,"May 10, 2013",the new drug application (NDA) for BREO ELLIPTA (NDA 204275),981
2016-03542,,"8,419,788",IDEV Technologies Inc,1894,1396,498,,,"March 28, 2014","the date the investigational device exemption (IDE) required under section 520(g) of the FD&C act for human tests to begin became effective January 21, 2009.
                

                    2. 
                    The date an application",158
2016-04369,,"8,222,219","Mitsubishi Tanabe Pharma Corporation of Osaka, Japan, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",2137,1834,303,,,"March 29, 2013",the new drug application (NDA) for INVOKANA (NDA 204042),256
2016-04370,,"7,488,827","Glaxo Group Limited, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",1589,1223,366,,,"December 18, 2013",the new drug application (NDA) for ANORO ELLIPTA (NDA 203975),966
2016-05389,,"7,094,781",Actelion Pharmaceuticals Ltd,1935,1570,365,,,"October 18, 2013",the new drug application (NDA) for OPSUMIT (NDA 204410),1151
2016-07477,,"7,144,884",H,2343,1979,364,,,"September 30, 2013",the new drug application (NDA) for BRINTELLIX (NDA 204447),1353
2016-08338,,,"Genentech, Inc",1698,1504,194,"March 11, 2009",,"November 1, 2013",the date the investigational new drug application became effective,
2016-08337,,"7,173,037","Bayer Intellectual Property GmbH, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",2394,2151,243,,,"October 8, 2013",the new drug application (NDA) for ADEMPAS (NDA 204819),1317
2016-08333,,"6,890,929",Pfizer Inc,2226,2172,54,,,"May 14, 2013",the date the investigational new animal drug application (INAD) became effective,1139
2016-08334,,"5,753,646","BIAL-PORTELA & CA, S",2517,832,1685,,,"November 8, 2013",NDA 22-416,1826
2016-08692,,"7,498,414",Eli Lilly and Co,3521,3279,242,,,"April 21, 2014",the date the investigational new drug application (IND) became effective,1059
2016-09374,,"5,900,488",Nihon Nohyaku Co,2242,1903,339,,,"November 14, 2013",the new drug application (NDA) for LUZU (NDA 204153),1289
2016-12708,,,"Medivir AB and Janssen R&D Ireland, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",2006,1766,240,,,"November 22, 2013",the new drug application (NDA) for OLYSIO (NDA 205123),
2016-12823,,"6,245,819",Hormos Medical Ltd,3585,3278,307,,,"February 26, 2013",the new drug application (NDA) for OSPHENA (NDA 203505),1826
2016-12829,,"7,427,638","Celgene Corporation, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",3494,3128,366,,,"March 21, 2014",the new drug application (NDA) for OTEZLA (NDA 205437),
2016-12859,,"7,378,423","Japan Tobacco, Inc",1842,1542,300,,,"May 29, 2013",NDA 204-114,623
2016-13526,,,Biogen Idec Hemophilia Inc,2223,1767,456,,,"March 28, 2014",the date the investigational new drug application (IND) became effective,
2016-13521,,,Biogen Idec Hemophilia Inc,1695,1239,456,,,"June 6, 2014",BLA 125487/0,1049
2016-13797,,"7,141,547","Human Genome Sciences, Inc",3014,2557,457,,,"April 15, 2014",the date the investigational new drug application (IND) became effective,1577
2016-13796,,,"Celgene Corporation, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",3716,3411,305,,,"February 8, 2013",the new drug application (NDA) for POMALYST (NDA 204026),
2016-14353,,"5,840,684",Eli Lilly and Co,6539,6295,244,,,"August 6, 2014",the new drug application (NDA) for ORBACTIV (NDA 206334),
2016-14357,,,"Boston Scientific Scimed, Inc",3075,2180,895,,,"November 15, 2012",,
2016-14356,,"6,299,604","Cook Medical Technologies, LLC, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",3075,2180,895,,,"November 14, 2012",the date the investigational device exemption (IDE) required under section 520(g) of the FD&C Act for human tests to begin became effective,1826
2016-14551,,"6,635,234","Algeta ASA, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",1945,1792,153,,,"May 15, 2013",the new drug application (NDA) for XOFIGO (NDA 203971),1032
2016-17187,,"6,239,180","NeurogesX, Inc",2944,2547,397,,,"November 16, 2009",NDA 22-395,1687
2016-22344,,"7,147,851","Millenium Pharmaceuticals, Inc",5066,4731,335,,,"May 20, 2014",the biologics license application (BLA) for ENTYVIO (BLA 125476),1526
2016-22345,,"5,686,060","Bracco Suisse SA, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",7199,6174,1025,,,"October 10, 2014",NDA 203684,
2016-22343,,"5,454,779","University of California and Advanced Circulatory Systems, Inc",3608,2247,1361,,,"March 6, 2015",the premarket approval application (PMA) for RESQCPR SYSTEM (PMA P110024),
2016-22935,,"6,001,968 from The Rockefeller University, and U.S. Patent No. 7,183,254 from Amgen, Inc.; The Board of Regents, The University of Texas System; and the Secretary, United States Department of Health and Human Services, National Institutes of Health",,6509,6174,335,,,"February 24, 2014",BLA 125-390,
2016-22933,,"6,949,571",Eisai R&D Management Co,3274,2968,306,,,"October 22, 2012",NDA 202834,1549
2016-22937,,,"Arena Pharmaceuticals, Inc",2928,2009,919,,,"June 27, 2012",NDA 22-529,
2016-23330,,"5,697,896",Alza Corp,4835,3862,973,,,"May 22, 2006",the new drug application (NDA) for IONSYS (NDA 21-338),
2016-25221,,,Amgen Inc,2267,1901,366,"June 14, 2009",,"August 27, 2015",the date the investigational new drug application became effective,
2016-25222,,,Biogen Idec MA Inc,2643,2186,457,"May 23, 2007",,"August 15, 2014",the date the investigational new drug application became effective,
2016-25220,,"5,817,338","AstraZeneca AB, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",2045,804,1241,,,"June 20, 2003",the new drug application (NDA) for PRILOSEC OTC (NDA 21-229),623
2016-28049,,"6,709,655","Instituto Bioclon, SA de CV, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",4223,3443,780,"October 15, 2003",,"May 6, 2015",the date the investigational new drug application became effective,
2016-28046,,,Pharming Intellectual Property B,3502,3045,457,,,"July 16, 2014",the biologics license application (BLA) for RUCONEST (BLA 125495),
2016-28045,,"7,196,205","Genzyme Corporation, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",3854,3520,334,"February 1, 2004",,"August 19, 2014",the date the investigational new drug application became effective,1518
2016-28047,,,,1194,1017,177,,,"January 17, 2014",,
2016-28653,,,"the University of North Carolina at Chapel Hill, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",2437,1318,1119,"August 28, 2008",,"April 29, 2015",the date the investigational new drug application became effective,
2016-28654,,"7,572,619","Octapharma AG, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",2622,2165,457,"July 2, 2008",,"September 4, 2015",the date the investigational new drug application became effective,1336
2016-28916,,,"Wyeth Holdings LLC, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",2079,1943,136,"February 20, 2009",,"October 29, 2014",the date the investigational new drug application became effective,255
2016-28917,,"8,008,449",E,3071,2925,146,,,"December 22, 2014",,
2016-28939,,"7,615,532","Novo Nordisk A/S, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",2914,1456,1458,,,"September 25, 2015",the new drug application (NDA) for TRESIBA (NDA 203-314),1803
2016-29025,,,"GlaxoSmithKline Biologicals SA, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",3963,3779,184,"March 20, 2004",,"January 23, 2015",the date the investigational new drug application became effective,
2016-29303,,,Merck Sharp & Dohme Corp,92662,2296,366,,,"December 10, 2014",the biologics license application (BLA) for GARDASIL 9 (BLA 125508/0),
2016-29838,,"5,693,323","GlaxoSmithKline LLC, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",6862,6496,366,,,"November 4, 2015",the biologics license application (BLA) for NUCALA (BLA 125526),
2016-30399,,"7,452,966","Eli Lilly and Company, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",3303,2937,366,"September 4, 2005",,"September 18, 2014",the date the investigational new drug application became effective,1249
2016-30528,,"7,807,155","Novartis AG, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",3381,2926,455,,,"January 21, 2015",the biologics license application (BLA) for COSENTYX (BLA 125504/0),629
2016-31322,,,"BioVex Limited, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",3809,3352,457,"May 25, 2005",,"October 27, 2015",the date the investigational new drug application became effective,
2017-00108,,"7,709,610","AbbVie Biotherapeutics, Inc",3400,3245,155,"August 11, 2006",,"November 30, 2015",the date the investigational new drug application became effective,1095
2017-00095,,,"Nektar Therapeutics, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",1061,707,354,"December 19, 2012",,"November 13, 2015",the date the investigational new drug application became effective,708
2017-12323,,"5,856,529","Vanda Pharmaceuticals, Inc",5802,5556,246,,,"January 31, 2014",the new drug application (NDA) for HETLIOZ (NDA 205677),
2017-12322,,,"NeuroPace, Inc",3796,2694,1102,,,"November 14, 2013",the date the investigational device exemption (IDE) required under section 520(g) of the FD&C Act for human tests to begin became effective,
2017-12359,,"5,496,801",NPS Pharmaceuticals Inc,7268,6811,457,,,"January 23, 2015",the biologics license application (BLA) for NATPARA (BLA 125511),
2017-14454,,,"Cerus Corporation, and the USPTO requested FDA's assistance in determining this patents' eligibility for patent term restoration",6497,6114,383,,,"December 16, 2014",PMA BP130076,
2017-14455,,,"Cerus Corporation, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",7080,6909,171,,,"December 18, 2014",,
2017-16516,,"RE39,548","UCB Celltech, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",5685,5325,360,,,"March 23, 2016",the biologics license application (BLA) for CINQAIR (BLA 761033),1660
2017-16515,,,Baxalta GmbH and Baxalta Inc,2690,2335,355,,,"December 8, 2015",the biologics license application (BLA) for VONVENDI (BLA 125577),
2017-17566,,,Acrux DDS Pty,2092,2037,55,,,"June 23, 2012",NADA 141-337,
2017-17961,,,,,,,,,,,
2017-18379,,"6,133,260",Alcon Pharmaceutials Ltd,1880,1643,237,"October 26, 2009",,"December 17, 2014",the date the investigational new drug application became effective,1058
2017-18380,,,"AstraZeneca UK Limited, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",6122,5338,784,,,"June 22, 2015",the new drug application (NDA) for KENGREAL (NDA 204958),
2017-21421,,"5,804,420","Bayer HealthCare LLC, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",2478,2021,457,"June 5, 2009",,"March 16, 2016",the biologics license application (BLA) for KOVALTRY (BLA 125574/0),1466
2017-21435,,,"Biogen Idec International GmbH, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",2480,2085,,,,"March 27, 2013",the date the investigational new drug application (IND) became effective,
2017-21436,,"5,911,685","Abiomed Europe GmbH, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",253227,2858,369,,,"March 23, 2015",the date the investigational device exemption (IDE) required under section 520(g) of the FD&C Act for human tests to begin became effective,1796
2017-22898,,"7,576,181",Emory University and (U,4216,3883,333,,,"October 23, 2014",BLA 125512/0,
2017-22895,,,,3846,2515,1331,,,"October 24, 2013",,
2017-22897,,"6,021,352","Inspire Medical Systems, Inc",2002,1653,349,,,"April 30, 2014","the date the investigational device exemption required under section 520(g) of the FD&C Act for human tests to begin became effective on November 7, 2008.
                

                    2. 
                    The date an application",1184
2017-25676,,,"BioCryst Pharmaceuticals, Inc",3287,2925,362,,,"December 19, 2014",NDA 206426,
2017-25683,,"7,420,051","Pharma Mar, S",7107,6773,334,"May 10, 1996",,"October 23, 2015",the date the investigational new drug application became effective,1471
2017-25703,,"7,365,205",Daiichi Sankyo Co,3845,3479,366,,,"January 8, 2015","July 1, 2004, is the date the investigational new drug application (IND) became effective.
                

                    2. 
                    The date the application",1406
2017-25682,,"7,129,232","Astellas Pharma, Inc",2360,2117,243,"July 5, 2008",,"December 19, 2014",the date the investigational new drug application became effective,1302
2017-25684,,,"Nevro Corporation, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",1136,820,316,,,"May 8, 2015",the date the investigational device exemption (IDE) required under section 520(g) of the FD&C Act for human tests to begin became effective,
2017-25770,,"6,258,795",Wellstat Therapeutics Corp,8494,8254,240,,,"September 4, 2015",the new drug application (NDA) for XURIDEN (NDA 208169),
2017-25761,,"8,147,873","Relypsa, Inc",2844,2478,366,,,"October 21, 2015","January 9, 2008, is the date the investigational new drug application (IND) became effective.
                

                    2. 
                    The date the application",832
2017-25772,,"7,888,362",Otsuka Pharmaceutical Co,2636,2271,365,,,"July 10, 2015",the new drug application (NDA) for REXULTI (NDA 205422),868
2017-25773,,"6,150,085","Haemonetics Corporation, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",1250,708,542,,,"April 25, 2013",the new drug application (NDA) for SOLX SYSTEM (NDA BN110059),894
2017-25780,,,Ajinomoto Co,4967,3091,1876,,,,,
2017-27684,,"7,816,379","Trius Therapeutics, Inc",2366,2123,243,,,"June 20, 2014",the new drug application (NDA) for SIVEXTRO (NDA 205435),118
2017-27745,,,,1271,1144,127,,,"April 29, 2014",,
2017-27710,,"7,727,984",Boehringer Ingelheim Pharma GmbH & Co,2712,1903,809,,,"July 31, 2014",the new drug application (NDA) for STRIVERDI RESPIMAT (NDA 203108),1166
2018-00353,,,"AstraZeneca Pharmaceuticals LP, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",4269,3964,305,"August 29, 2002",,"May 5, 2014",the date the investigational new drug application became effective,
2018-00358,,,RaQualia Pharma Inc,1645,1589,56,,,"May 16, 2016",NADA 141-457,
2018-00355,,,"Medtronic, Inc",788,585,203,,,"April 6, 2016",the premarket approval application (PMA) for MICRA TRANSCATHETER PACING SYSTEM (PMA P150033),
2018-00404,,,"Uromedica, Inc",3892,3179,713,,,"November 24, 2015",PMA 130018,
2018-00675,,"8,329,159","Bristol-Myers Squibb Company, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",2808,2327,481,,,"July 24, 2015",the new drug application (NDA) for DAKLINZA (NDA 206843),467
2018-00678,,"7,112,592",Forest Laboratories Holdings Ltd,2579,2333,246,,,"February 25, 2015","February 5, 2008, is the date the investigational new drug application (IND) became effective.
                

                    2. 
                    The date the application",1411
2018-00684,,"5,808,146","Emory University, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",4006,3763,243,"June 10, 2005
                

                    2",,"May 27, 2016",the date the investigational new drug application became effective,
2018-00679,,"8,348,992","Boston Scientific Scimed, Inc",1206,950,256,,,"October 2, 2015",the date the investigational device exemption (IDE) required under section 520(g) of the FD&C Act for human tests to begin became effective,629
2018-00994,,,"Millennium Pharmaceuticals, Inc",2538,2404,134,"December 10, 2008",,"November 20, 2015",the date the investigational new drug application became effective,
2018-00992,,,"Ardea Biosciences, Inc",2245,1886,359,"October 31, 2009",,"December 22, 2015",the date the investigational new drug application became effective,
2018-00995,,"8,540,768",Sorin Group Italia S,1003,694,309,,,"January 8, 2016",PMA P150011,576
2018-01373,,"7,049,320","OPKO Health, Inc",3070,2708,362,"April 8, 2007",,"September 1, 2015",the date the investigational new drug application became effective,1716
2018-01368,,,"Forest Laboratories, LLC, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",3742,2709,1033,"June 21, 2005",,"September 17, 2015",the date the investigational new drug application became effective,
2018-01637,,"7,205,302","Actelion Pharmaceuticals, Ltd",2246,1881,365,"October 29, 2009",,"December 21, 2015",the date the investigational new drug application became effective,1305
2018-01642,,"7,973,040",Merck Sharp & Dohme Corp,1865,1619,246,"December 22, 2010",,"January 28, 2016",the date the investigational new drug application became effective,188
2018-01640,,"7,960,407",AskAt Inc,1688,1636,52,,,"March 21, 2016, however, FDA records indicate that NADA 141-455 was approved on Sunday, March 20, 2016",,899
2018-01641,,,Taiho Pharmaceutical Co,6083,5805,278,,,"September 22, 2015",the new drug application (NDA) for LONSURF (NDA 207981),
2018-01651,,"8,501,238",AbbVie Inc,2391,2148,243,,,"December 19, 2014","June 4, 2008, is the date the investigational new drug application (IND) became effective.
                

                    2. 
                    The date the application",93
2018-01644,,"7,839,153","CardioMEMS, Inc",2786,1525,1261,,,"May 28, 2014","the date the investigational device exemption required under section 520(g) of the FD&C Act for human tests to begin became effective October 13, 2006.
                

                    2. 
                    The date an application",1026
2018-01655,,,"Edwards Lifesciences PVT, Inc",31736,1558,178,,,"June 17, 2015",PMA P140031,
2018-01645,,,Basilea Pharmaceutica International Ltd,3528,3286,242,,,"March 6, 2015","July 10, 2005, is the date the investigational new drug application (IND) became effective.
                

                    2. 
                    The date the application",
2018-01920,,"7,253,286",EISAI R&D Management Co,3580,3396,184,,,"February 13, 2015","April 28, 2005, is the date the investigational new drug application (IND) became effective.
                

                    2. 
                    The date the application",1465
2018-01894,,,"Wyeth LLC, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",5683,5317,366,,,"October 3, 2013",the new drug application (NDA) for DUAVEE (NDA 022247),
2018-01890,,"8,354,509",Merck Sharp & Dohme B,44941338,1148,190,,,"September 4, 2014",the biologics license application (BLA) for KEYTRUDA (BLA 125514/0),83
2018-01889,,"8,627,999",Beaurain et al,2758,1821,937,,,"August 7, 2013",the premarket approval application (PMA) for MOBI-C CERVICAL DISC PROSTHESIS (PMA P110002),323
2018-01891,,,"Edwards Lifesciences PVT, Inc",1370,959,411,,,"June 16, 2014",the date the investigational device exemption became effective,
2018-01892,,,Basilea Pharmaceutica International Ltd,3528,3286,242,"July 10, 2005",,"March 6, 2015",the date the investigational new drug application became effective,
2018-01979,,,"Les Laboratoires Servier, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",293,0,293,,,"April 15, 2015",the new drug application (NDA) for CORLANOR (NDA 206143),
2018-02187,,,"Janssen Pharmaceutica, N",2716,2381,335,,,"May 27, 2015","December 21, 2007, is the date the investigational new drug application (IND) became effective.
                

                    2. 
                    The date the application",
2018-02418,,,"AstraZeneca AB, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",3673,2565,1108,"December 21, 2003",,"January 8, 2014",NDA 202293,
2018-02419,,,"Amgen Research (Munich) GMBH, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",2850,2774,76,"February 15, 2007",,"December 3, 2014",the biologics license application (BLA) for BLINCYTO (BLA 125557),
2018-02403,,,"Gilead Sciences, Inc",5031,4665,366,,,"November 5, 2015",the new drug application (NDA) for GENVOYA (NDA 207561),1116
2018-02432,,"6,807,965","Scott Laboratories, Inc",2816,950,1866,,,"May 3, 2013",the premarket approval application (PMA) for SEDASYS SYSTEM (PMA P080009),2283
2018-02522,,"7,214,506",Kaken Pharmaceutical Co,2521,1840,681,,,"June 6, 2014",the date the investigational new drug application (IND) became effective,1601
2018-02588,,"7,763,712","Alexion Pharmaceuticals, Inc",2670,2365,305,,,"October 23, 2015",the biologics license application (BLA) for STRENSIQ (BLA 125513),1109
2018-02658,,"8,178,563","Novartis AG, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",2414,2112,302,,,"July 24, 2015","December 15, 2008, is the date the investigational new drug application (IND) became effective.
                

                    2. 
                    The date the application",169
2018-02666,,"7,939,632","CSL Behring GmbH, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",1479,1023,456,"February 17, 2012",,"March 4, 2016",the date the investigational new drug application became effective,531
2018-02591,,"7,449,464","Kudos Pharmaceuticals Limited, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",3012,2692,320,,,"December 19, 2014","September 22, 2006, is the date the investigational new drug application (IND) became effective.
                

                    2. 
                    The date the application",1275
2018-02590,,,"Merrimack Pharmaceuticals, Inc",2536,2354,182,,,"October 22, 2015","November 13, 2008, is the date the investigational new drug application became effective.
                

                    2. 
                    The date the application",
2018-02592,,,"Novartis Pharmaceuticals Corporation, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",3148,2945,203,,,"July 7, 2015",the new drug application (NDA) for ENTRESTO (NDA 207620),
2018-02582,,"8,460,374","AcuFocus, Inc",2347,1541,806,,,"April 17, 2015",the date the investigational device exemption (IDE) required under section 520(g) of the FD&C Act for human tests to begin became effective,676
2018-02791,,"8,008,309","Pharmacyclics, Inc",1865,1726,139,,,"November 13, 2013",the new drug application (NDA) for IMBRUVICA (NDA 205552),320
2018-02768,,"6,900,175","Vicuron Pharmaceuticals, Inc",5033,1592,3441,,,"May 23, 2014",the new drug application (NDA) for DALVANCE (NDA 21883),1612
2018-02763,,"7,951,797",Merck Sharp & Dohme Corp,2291,1577,714,,,"August 13, 2014","the new drug application (NDA) for BELSOMRA (NDA 204569) 
                    

      ( print page 6036)",
2018-02756,,"6,297,375",Hoffmann-La Roche Inc,1858,1479,379,,,"October 10, 2014","September 10, 2009, is the date the investigational new drug application (IND) became effective.
                

                    2. 
                    The date the application",1118
2018-02767,,"RE43,431",Boehringer Ingelheim Pharma Gmbh & Co,3453,3213,240,,,"July 12, 2013",the new drug application (NDA) for GILOTRIF (NDA 201292),1057
2018-02761,,"7,662,972","Nissan Chemical Industries, Ltd",1017,979,38,,,"May 15, 2014",the new animal drug application (NADA) for BRAVECTO (NADA 141-426),792
2018-02851,,"8,188,146","Amarin Pharmaceuticals Ireland Limited, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",1133,828,305,,,"July 26, 2012",the new drug application (NDA) for VASCEPA (NDA 202057),58
2018-02868,,,"Novartis AG, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",4334,3997,337,,,"February 23, 2015",the new drug application (NDA) for FARYDAK (NDA 205353),
2018-03041,,"6,888,027","Spectrum Pharmaceuticals, Inc",3488,3281,207,,,"July 3, 2014",NDA 206256,1779
2018-03029,,,"Warner-Lambert Company, LLC, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",3954,3779,175,,,"February 3, 2015",the new drug application (NDA) for IBRANCE (NDA 207103),
2018-02992,,"7,579,449","Boehringer Ingelheim International GmbH, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",2275,1760,515,,,"August 1, 2014",the new drug application (NDA) for JARDIANCE (NDA 204629),1001
2018-02993,,"7,582,621","Anacor Pharmaceuticals, Inc",3112,2768,344,,,"July 7, 2014","December 31, 2005, is the date the investigational new drug application became effective.
                

                    2. 
                    The date the application",408
2018-02991,,"7,854,943","IDEXX, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",4034,3980,54,,,"November 4, 2014",NADA 141-437,235
2018-03017,,"7,741,476","Pierre Lebreton, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",1896,1110,786,,,"October 22, 2013",the premarket approval application (PMA) for JUVEDERM VOLUMA XC (PMA P110033),567
2018-03126,,,"Janssen Biotech, Inc",3747,3510,237,,,"April 23, 2014",the biologic license application (BLA) for SYLVANT (BLA 125496/0),
2018-03136,,"8,338,395","Bayer Intellectual Property GmbH, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",2923,541,2382,,,"March 5, 2014",the new drug application (NDA) for AVEED (NDA 022219),435
2018-03129,,RE43879,"Pierre Fabre Medicament, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",1602,1298,304,,,"July 25, 2013",NDA 204168,954
2018-03170,,"7,304,078",Merck Sharp & Dohme Corp,3401,3037,364,,,"May 8, 2014",the new drug application (NDA) for ZONTIVITY (NDA 204886),1357
2018-03137,,RE44733,"Merck Sharp & Dohme, B",4265,1297,2968,"April 13, 2004",,"December 15, 2015",the date the investigational new drug application became effective,1826
2018-03127,,,Vertex Pharmaceuticals Inc,2785,2545,240,,,"July 2, 2015","November 18, 2007, is the date the investigational new drug application (IND) became effective.
                

                    2. 
                    The date the application",
2018-03130,,,"Sprout Pharmaceuticals, Inc",6852,4730,,,,"August 18, 2015",,
2018-03134,,,"ICOS Corporation, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",2058582247,1931,316,,,"July 23, 2014",the date the investigational new drug application (IND) became effective,537
2018-03229,,"7,863,256",Fidia Farmaceutici S,1845,1665,180,,,"August 28, 2015",the premarket approval application (PMA) for HYMOVIS (PMA P150010),938
2018-03218,,,"Exelixis, Inc",3219,2884,335,,,"November 10, 2015",the new drug application (NDA) for COTELLIC (NDA 206192),
2018-03245,,,"Nektar Therapeutics, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",2493,2127,366,,,"September 16, 2014",the new drug application (NDA) for MOVANTIK (NDA 204760),
2018-03345,,"7,598,350","Eli Lilly and Company, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",2533,2175,358,"December 19, 2008",,"November 24, 2015",the date the investigational new drug application became effective,1321
2018-03342,,"7,829,673","Genmab A/S, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",1939,1808,131,"July 28, 2010",,"November 16, 2015",the date the investigational new drug application became effective,1000
2018-03343,,"7,672,727",EnteroMedics Inc,2866,2296,570,,,"January 14, 2015",PMA P130019,385
2018-03610,,"6,409,990","Navidea Biopharmaceuticals, Inc",4398,3816,582,"February 28, 2001",,"March 13, 2013",the date the investigational new drug application became effective,1826
2018-03606,,"6,762,180",Boehringer Ingelheim Pharma Gmbh & Co,3480,3313,167,,,"October 15, 2014",the new drug application (NDA) for OFEV (NDA 205832),1822
2018-03612,,,InterMune Inc,14993,13186,1807,,,"October 15, 2014",the new drug application (NDA) for ESBRIET (NDA 22-535),
2018-03701,,,"ICOS Corporation, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",2247,2017,230,,,"July 23, 2014",the date the investigational new drug application (IND) became effective,
2018-22571,,,"Janssen Biotech, Inc",2968,2728,240,,,"July 13, 2017",the biologics license application (BLA) for TREMFYA (BLA 761061),
2018-22566,,"7,608,693","Regeneron Pharmaceuticals, Inc",2728,2485,243,"October 10, 2009",,"March 28, 2017",the date the investigational new drug application became effective,1273
2018-22559,,"8,029,781","Rutgers, the State University of New Jersey, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",995,659,336,"August 8, 2014",,"April 27, 2017",the date the investigational new drug application became effective,666
2018-22699,,,"Genentech, Inc",4844,4509,335,"December 25, 2003",,"March 28, 2017",the date the investigational new drug application became effective,
2018-22696,,"7,041,635","SK Chemicals Co, LTD",1734,1371,363,"August 28, 2011",,"May 25, 2016",the date the investigational new drug application became effective,1047
2018-22806,,,"MedImmune Limited, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",1755,1554,201,"July 13, 2012",,"May 1, 2017",the date the initial investigational new drug application became effective,159
2018-22956,,,"Radius Health, Inc",4130,3735,395,,,"April 28, 2017",the date the investigational new drug application became effective,
2018-22958,,,"Wyeth Holdings LLC, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",5298,5057,241,"February 16, 2003",,"August 17, 2017",the date the investigational new drug application became effective,
2018-22957,,"8,217,149","Genentech, Inc",1836,1708,128,"May 11, 2011",,"May 18, 2016",the date the investigational new drug application became effective,769
2018-23057,,,ACADIA Pharmaceuticals Inc,4557,4315,242,,,"April 29, 2016",the date the investigational new drug application became effective,
2018-23058,,,"Kirin-Amgen, Inc",3101,2643,458,,,"February 15, 2017",the biologics license application (BLA) for SILIQ (BLA 761032),
2018-23219,,"8,128,929","Imclone LLC, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",3766,3527,239,,,"October 19, 2016",BLA 761038,1003
2018-23438,,,"Eli Lilly and Company, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",3036,2670,366,,,"March 22, 2016",the biologics license application (BLA) for TALTZ (BLA 125521),
2018-23437,,,"Novo Nordisk A/S, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",2793,2412,381,,,"May 31, 2017",the biologics license application (BLA) for REBINYN (BLA 125611/0),
2018-23527,,"8,057,541","ReVision Optics, Inc",2354,2074,280,,,"June 29, 2016",the date the investigational device exemption required under section 520(g) of the FD&C Act for human tests to begin became effective,828
2018-26033,,,"Regeneron Pharmaceuticals, Inc",3478,2907,571,"November 15, 2007",,"May 22, 2017",the date the investigational new drug application became effective,
2018-26035,,"8,765,942",Provepharm S,415,232,183,,,"April 8, 2016",the date the investigational new drug application became effective,298
2018-26289,,"7,041,786","Synergy Pharmaceuticals, Inc",3186,2829,357,,,"January 19, 2017",the date the investigational new drug application became effective,1771
2018-26288,,"7,138,390","Intercept Pharmaceuticals, Inc",3742,3408,334,,,"May 27, 2016",NDA 207999,1826
2018-26290,,"9,039,677","Aspire Bariatrics, Inc",2785,2444,341,,,"June 14, 2016",PMA P150024,385
2018-26282,,"6,612,988","Brigham and Women's Hospital, Inc",2050,1785,265,,,"July 11, 2016",the date the investigational device exemption (IDE) required under section 520(g) of the FD&C Act for human tests to begin became effective,1158
2018-27678,,,Abbott Cardiovascular Systems Inc,11303,932,371,,,"July 5, 2016",PMA P150023,1100841
2018-27805,,RE45313,ZP Holding SPV K/S and the USPTO requested FDA's assistance in determining the patent's eligibility for patent term restoration,5500,5133,367,,,"July 27, 2016",the date the investigational new drug application became effective,1826
2018-28221,,,"KAI Pharmaceuticals, Inc",2335,1801,534,"September 19, 2010",,"February 7, 2017",the date the investigational new drug application became effective,
2018-28218,,"7,709,493","Lexicon Pharmaceuticals, Inc",3329,2993,336,"January 20, 2008",,"February 28, 2017",the date the investigational new drug application became effective,1175
2018-28217,,"6,495,541","Agouron Pharmaceuticals, LLC and the USPTO requested FDA's assistance in determining the patent's eligibility for patent term restoration",2644,2464,180,"September 25, 2009",,"December 19, 2016",the date the investigational new drug application became effective,1412
2018-28216,,,Novartis AG and Dana-Farber Cancer Institute Inc,6737,6494,243,,,"April 28, 2017",,
2019-01851,,,the University of Western Australia and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration,512280,1828,452,,,"September 19, 2016",the date the investigational new drug application became effective,
2019-01956,,,"Anacor Pharmaceuticals, Inc",3121,2778,343,,,"December 14, 2016",the date the investigational new drug application became effective,
2019-02036,,"8,071,623",MSD Italia S,3234,3086,148,,,"March 27, 2017",the new drug application (NDA) for ZEJULA (NDA 208447),370
2019-02044,,,Newron Pharmaceuticals S,5019,4205,814,,,"March 21, 2017",NDA 207145,
2019-07459,,RE46365,Shionogi & Co,2523,2157,366,,,"March 23, 2017",the date the investigational new drug application became effective,1140
2019-08609,,"7,741,465",Cabaret Biotech Ltd,3243,3041,202,,,"October 18, 2017",the date the investigational new drug application became effective,1498
2019-09805,,"8,524,733","Auspex Pharmaceuticals, Inc",1736,1060,676,,,"April 3, 2017",the date the investigational new drug application became effective,8
2019-09817,,"6,461,665",W,1136,931,205,,,"January 27, 2017","the date the investigational device exemption required under section 520(g) of the FD&C Act for human tests 
                    

      ( print page 20896)
    
                    to begin became effective",669
2019-10889,,"8,911,493",Edwards Lifesciences Corp,1508,1203,305,,,"August 12, 2016","the date the investigational device exemption (IDE) required under section 520(g) of the FD&C Act for human tests to begin became effective on June 28, 2012.
                

                    2. 
                    The date an application",605
2019-12320,,"9,012,462","ARIAD Pharmaceutials, Inc",2105,1862,243,,,"April 28, 2017",the date the investigational new drug application became effective,81
2019-12305,,,Novartis AG and Astex Therapeutics Ltd,2393,2196,197,"August 26, 2010",,"March 13, 2017",the date the investigational new drug application became effective,
2019-12299,,,"Melinta Therapeutics, Inc",5813,5569,244,,,"June 19, 2017",the new drug application (NDA) for BAXDELA (NDA 208610),
2019-12298,,,"Melinta Therapeutics, Inc",5813,5569,244,,,"June 19, 2017",the NDA 208611 for BAXDELA IV INJECTION,
2019-18816,,,"Puma Biotechnology, Inc",5102,4738,364,,,"July 17, 2017",the date the investigational new drug application became effective,
2019-18805,,"8,029,992","Vericel Corporation, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",345,0,345,,,"December 13, 2016",the biologics license application (BLA) for MACI (BLA 125603),345
2019-18788,,,"Millennium Pharmaceuticals, Inc",4244,4001,243,,,"June 23, 2017",the new drug application (NDA) for BEVYXXA (NDA 208383),
2019-19110,,"9,572,856",George Washington University and the USPTO requested FDA's assistance in determining the patent's eligibility for patent term restoration,1639,1463,176,,,"December 21, 2017",the new drug application (NDA) for GIAPREZA (NDA 209360),241
2019-19205,,"7,939,084","GlaxoSmithKline Biologicals SA, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",3257,2892,365,,,"October 20, 2017",the biologics license application (BLA) for SHINGRIX (BLA 125614),1361
2019-19496,,"8,574,226","Tsunami MedTech, LLC, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",1381,1148,233,,,"June 14, 2017","the date the investigational device exemption (IDE) for human tests to begin, as required under section 520(g) of the FD&C Act, became effective September 4, 2013.
                

                    2. 
                    The date an application",931
2019-19600,,,"Edwards Lifesciences Corporation, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",1858,1491,367,,,"June 29, 2017","the date the investigational device exemption (IDE) for human tests to begin, as required under section 520(g) of the FD&C Act, became effective May 30, 2012.
                

                    2. 
                    The date an application",
2019-20657,,"7,917,224","Med-El Electromedizinische Gerate GmbH, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",4537,4269,268,,,"September 15, 2016",the premarket approval application (PMA) for MED-EL EAS (PMA P000025 S084),998
2019-25821,,,"Indiana University Research and Technology Institute and Ludwig-Maximilians-Universtat Munchen, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",3485,3241,244,,,"April 17, 2018",,
2019-25850,,"8,129,343","Novo Nordisk A/S, and the USPTO requested FDA's assistance in determining the patent's eligibility for patent term restoration",3336,2970,366,"October 19, 2008",,"December 5, 2017",the date the investigational new drug application became effective,1040
2019-26081,,"9,102,731","Amgen, Inc",2042,1675,367,"October 16, 2012",,"May 17, 2018",the date the investigational new drug application became effective,689
2019-26252,,"9,433,688","Trustees of the University of Pennsylvania, the University of Florida Research Foundation, Inc",3809,3591,218,"July 18, 2007",,"December 19, 2017",the date the investigational new drug application became effective,344
2019-26251,,,"Portola Pharmaceuticals, Inc",2171,1302,869,"May 25, 2012",,"May 3, 2018",the date the investigational new drug application became effective,
2019-26327,,,Biomarin Pharmaceutical Inc,3803,3474,329,"December 27, 2007",,"May 24, 2018",the date the investigational new drug application became effective,
2019-26655,,"8,680,136","Rempex Pharmaceuticals, Inc",1316,1072,244,,,"August 29, 2017",the new drug application (NDA) for VABOMERE (NDA 209776),12
2019-26812,,"6,784,197",UCB Biopharma SPRL and the USPTO requested FDA's assistance in determining the patent's eligibility for patent term restoration,2058374293,3753,540,,,"February 18, 2016",NDA 205837 for BRIVIACT INJECTION,1547
2019-26813,,"6,911,461",UCB Biopharma SPRL and the USPTO requested FDA's assistance in determining the patent's eligibility for patent term restoration,4293,3753,540,,,"February 18, 2016",the date the investigational new drug application (IND) became effective,
2019-26814,,"8,492,416",UCB Biopharma SPRL and the USPTO requested FDA's assistance in determining the patent's eligibility for patent term restoration,4293,3753,540,,,"February 18, 2016",the NDA for BRIVIACT ORAL SOLUTION (NDA 205838),698
2020-00936,,,"AbbVie, Inc",1725,1492,233,,,"August 3, 2017",the date the investigational new drug applications became effective,
2020-03115,,,"Endorecherche, Inc",3381,2983,398,,,"November 16, 2016",the date the investigational new drug application became effective,
2020-04362,,,Merck Sharp & Dohme Corp,3452,3089,363,"October 8, 2008",,"March 20, 2018",the date the investigational new drug application became effective,
2020-04363,,,Kyowa Hakko Kirin Co,4127,3763,364,,,"November 14, 2017",the biologics license application (BLA) for FASENRA (BLA 761070),
2020-04545,,"8,039,627","Neurocrine Biosciences, Inc",2071,1827,244,,,"April 11, 2017",NDA 209241,552
2020-15011,,"5,981,826","Cartiva, Inc",2407,1979,428,,,"July 1, 2016",PMA 150017,1429
2020-15013,,"6,335,447",Toyama Chemical Co,2819,2282,537,,,"December 11, 2017",the date the investigational new drug application became effective,1678
2020-15295,,,"Glaukos Corporation, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",2508,2330,178,,,"June 21, 2018","the date the investigational device exemption for human tests to begin, as required under section 520(g) of the FD&C Act became effective,",
2020-18239,,"8,501,439",Dompe Farmaceutici S,1484,1240,244,"August 1, 2014",,"August 22, 2018",the date the investigational new drug application became effective,863
2020-18240,,,"Palatin Technologies, Inc",6721,6265,456,,,"June 21, 2019",the new drug application (NDA) for VYLEESI (NDA 210557),
2020-19036,,,"Kyowa Hakko Kirin, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",3536,3227,309,"December 4, 2008",,"August 8, 2018",the date the investigational new drug application became effective,
2020-19085,,,"Scott & White Memorial Hospital, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",5541,5357,184,,,"December 21, 2018",,
2020-19214,,,the U,4320,4092,228,"November 17, 2006",,"September 13, 2018",the date the investigational new drug application became effective,
2020-20040,,"6,400,974","Senseonics, Inc",3727,3123,604,,,"June 21, 2018",the premarket approval application (PMA) for EVERSENSE CGM SYSTEM (PMA P160048),
2020-20104,,"8,816,055",Dyax Corp,1857,1616,241,,,"August 23, 2018",the biologics license application (BLA) for TAKHZYRO (BLA 761090),849
2021-05372,,"6,100,082","TransMedics, Inc",2341,1672,669,,,"March 22, 2018",PMA P160013,1687
2021-05371,,"6,409,767","European Foot Platform, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",34676,3661,1015,,,"June 4, 2019",the date on which the device is first used with human subjects as part of a clinical investigation to be filed with FDA to secure premarket approval of the device,1825
2021-06210,,,"CVRx, Inc",2550,2310,240,,,"August 16, 2019",PMA 180050,
2021-06693,,"8,541,448","Ardelyx, Inc",3219,2853,366,,,"September 12, 2019",the new drug application (NDA) for IBSRELA (NDA 211801),1272
2021-06696,,,"SIGA Technologies, Inc",4601,4383,218,,,"July 13, 2018",the new drug application (NDA) for TPOXX (NDA 208627),
2021-06709,,"9,314,353","Veryan Medical Limited, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",31234,973,261,,,"October 4, 2018",the premarket approval application (PMA) for BIOMIMICS 3D VASCULAR STENT SYSTEM (PMA 180003),580
2021-12192,,,Impulse Dynamics N,5434,5236,198,,,"March 21, 2019","the date the investigational device exemption for human tests to begin, as required under section 520(g) of the FD&C Act, became effective May 6, 2004.
                

                    2. 
                    The date an application",
2021-12148,,,"Bioprojet, and the USPTO requested FDA's assistance in determining the patent's eligibility for patent term restoration",505,261,244,,,"August 14, 2019",the new drug application (NDA) for WAKIX (NDA 211150),
2021-12189,,,"SANOFI, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",3718,3410,308,,,"March 2, 2020","the date the investigational new 
                    

      ( print page 30952)
    
                    drug application became effective",
2021-12193,,,Icahn School of Medicine at Mt,2456,2273,183,,,"March 5, 2019",,
2021-12199,,,Amgen Inc,4519,3524,995,,,"April 9, 2019",the biologics license application (BLA) for EVENITY (BLA 761062),
2021-12167,,"8,999,996",Karyopharm Therapeutics Inc,2585,2253,332,,,"July 3, 2019",NDA 212306,291
2021-12171,,,"Novartis AG, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",4544,4299,245,,,"March 26, 2019",the new drug application (NDA) for MAYZENT (NDA 209884),
2021-12284,,,,1054,1016,38,,,,,
2021-13176,,"9,133,461","Alnylam Pharmaceuticals, Inc",1533,1363,170,"September 11, 2015",,"November 20, 2019",the date the investigational new drug application became effective,190
2021-13186,,,Plexxikon Inc,3637,3394,243,"August 19, 2009",,"August 2, 2019",the date the investigational new drug application became effective,
2021-13411,,"7,906,111","REGENXBIO, Inc",2088,1852,236,,,"May 24, 2019",the biologics license application (BLA) for ZOLGENSMA (BLA 125694),1162
2021-13743,,"8,410,088","Epizyme, Inc",1618,1372,246,"August 21, 2015",,"January 23, 2020",the date the investigational new drug application became effective,650
2021-13687,,"9,474,517",W,931,751,18034025,,,"May 28, 2019","the date the investigational device exemption (IDE) for human tests to begin, as required under section 520(g) of the FD&C Act, became effective November 10, 2016.
                

                    2. 
                    The date an application",556
2021-13686,,"7,335,364","Bavarian Nordic A/S, and the USPTO requested FDA's 
                    

      ( print page 34020)
    
                    assistance in determining this patent's eligibility for patent term restoration",5650,5315,335,,,"September 24, 2019","the biologics license application (BLA) for Smallpox and Monkeypox Vaccine, Live (BLA 125678)",1825
2021-13976,,,"Global Blood Therapeutics, Inc",1847,1694,153,"November 6, 2014",,"November 25, 2019",,
2021-13971,,"9,238,657",Shionogi & Co,2400,2064,336,,,"November 14, 2019",NDA 209445,726
2021-13973,,"8,895,601",Astex Therapeutics Ltd,2179,1972,207,"April 26, 2013",,"April 12, 2019",the date the investigational new drug application became effective,691
2021-13949,,,"Genentech, Inc",3050,2876,174,"February 4, 2011",,"June 10, 2019",the biologics license application (BLA) for POLIVY (BLA 761121),
2021-13972,,"7,331,499",Alfred E,681,494,187,,,"September 6, 2019","the date the investigational device exemption (IDE) for human tests to begin, as required under section 520(g) of the FD&C Act, became effective October 27, 2017.
                

                    2. 
                    The date an application",434
2021-14461,,"9,084,765",Acacia Pharma Limited and the USPTO requested FDA's assistance in determining the patent's eligibility for patent term restoration,2960,2085,875,"January 21, 2012",,"February 26, 2020",the date the investigational new drug application became effective,1085
2021-14473,,,"Novartis AG, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",3064,2821,243,"May 20, 2011",,"October 7, 2019",the biologics license application (BLA) for BEOVU (BLA 761125),
2021-14482,,,Pulmonx Corp,5744,5565,179,,,"June 29, 2018",PMA 180002,
2021-14490,,,Novartis AG and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration,3264,3106,158,"June 18, 2010",,"May 24, 2019",the date the investigational new drug application became effective,
2021-14652,,"8,007,794","Teva Pharmaceuticals International GmbH, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",3216,2882,334,,,"September 14, 2018",the biologics license application (BLA) for AJOVY (BLA 761089),1454
2021-23074,,"8,975,254","Orion Corporation, and the USPTO requested FDA's assistance in determining the patent's eligibility for patent term restoration",586722576,2420,156,"July 13, 2012",,"July 30, 2019",the date the investigational new drug application became effective,879
2021-23388,,,"Impact Biomedicines, Inc",4285,4059,226,"November 24, 2007",,"August 16, 2019",,
2021-23387,,,Nabriva Therapeutics GMBH and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration,3595,3351,244,"October 17, 2009",,"August 19, 2019",the date the investigational new drug application became effective,
2021-23386,,,"Nabriva Therapeutics GMBH, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",3595,3351,244,"October 17, 2009",,"August 19, 2019",the date the investigational new drug application became effective,
2021-23719,,,,1891,1799,92,"October 22, 2011",,"December 23, 2016",,
2021-23725,,,"Daiichi Sankyo Company, Limited, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",1395,186,1209,"February 26, 2016",,"December 20, 2019",the date the investigational new drug application became effective,
2021-23724,,,"The University of Western Australia, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",531833,1474,359,,,"December 12, 2019",the new drug application (NDA) for VYONDYS 53 (NDA 211970),
2021-24070,,,"Novartis AG, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",3152,2968,184,"April 1, 2011",,"November 15, 2019",the date the investigational new drug application became effective,
2021-24074,,"8,334,265","Clinuvel Pharmaceuticals Limited, and the USPTO requested FDA's assistance in determining the patent's eligibility for patent term restoration",3914,3579,335,"January 21, 2009",,"October 8, 2019",the date the investigational new drug application became effective,1481
2021-24065,,"9,029,316",Laboratoire Francais du Fractionnement et des Biotechnologies S,2785,1518,1267,,,"April 1, 2020",the biologics license application (BLA) for SEVENFACT (BLA 125641),482
2021-24077,,,"Galderma Research & Development, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",3137,2771,366,,,"October 4, 2019",the new drug application (NDA) for AKLIEF (NDA 211527),
2021-24067,,"8,142,795","Sanofi Pasteur, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",5710,5466,244,"September 14, 2003",,"May 1, 2019",the date the investigational new drug application became effective,1248
2021-24068,,"8,487,093",Merck Sharp & Dohme Corp,3200,2957,243,"October 13, 2010",,"July 16, 2019",the date the investigational new drug application became effective,1218
2021-24435,,,Ultragenyx Pharmaceutical Inc,2511,2175,336,"August 17, 2013",,"June 30, 2020",,
2021-24978,,,Deciphera Pharmaceuticals LLC and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration,1741,1586,155,"August 11, 2015",,"May 15, 2020",,
2021-25297,,"8,440,715","JAZZ Pharmaceutials, Inc",8209,7664,545,,,"March 20, 2019, and that the Drug Enforcement Administration issued an interim final rule controlling the product on June 17, 2019",the new drug application (NDA) for SUNOSI (NDA 211230),1386
2021-25612,,"7,999,083","Immunomedics, Inc",2856,2150,706,"June 29, 2012",,"April 22, 2020",the date the investigational new drug application became effective,1780
2021-26009,,"7,763,615","Pharma Mar, S",4170,3987,183,,,"June 15, 2020",the new drug application (NDA) for ZEPZELCA (NDA 213702),1826
2022-00404,,,,1395,114,1281,,,,,
2022-13860,,"9,315,585","Memorial Sloan Kettering Cancer Center, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",3423,3183,240,"July 15, 2011",,"November 25, 2020",the date the investigational new drug application became effective,3421
2022-13856,,"8,168,615","ViiV Healthcare UK, and the USPTO requested FDA's assistance in determining the patent's eligibility for patent term restoration",5322,5110,212,,,"July 2, 2020",the new drug application (NDA) for RUKOBIA (NDA 212950),1597
2022-13956,,"7,572,897",Hoffman-La Roche Inc,2958,2760,198,,,"January 21, 2020",the biologics license application (BLA) for TEPEZZA (BLA 761143),1578
2022-14134,,,"RHYTHM PHARMACEUTICALS, INC",3304,3060,244,,,"November 25, 2020",the new drug application (NDA) for IMCIVREE (NDA 213793),
2022-14350,,"9,745,373","AlderBio Holdings LLC, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",2599,2233,366,,,"February 21, 2020","the 
                    

      ( print page 40250)
    
                    biologics license application (BLA) for VYEPTI (BLA 761119)",637
2022-14357,,,"Xenocor, Inc",3806,3590,216,"March 3, 2010",,"July 31, 2020",the date the investigational new drug application became effective,
2022-14360,,"8,802,093","MacroGenics, Inc",3950,3585,365,,,"December 16, 2020",the biologics license application (BLA) for MARGENZA (BLA 761150),1342
2022-14430,,,Dr,4573,2797,1776,,,"July 24, 2020",the new drug application (NDA) for XEGLYZE (NDA 206966),
2022-14431,,,AbbVie and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration,2604,2365,239,"July 1, 2012",,"August 16, 2019",the date the investigational new drug application became effective,
2022-14539,,"8,323,653","Viela Bio, Inc",4033,3666,367,,,"June 11, 2020",the biologics license application (BLA) for UPLIZNA (BLA 761142),1557
2022-14548,,,"AGENSYS, Inc",2546,2389,157,,,"December 18, 2019",,
2022-14546,,,"Genentech, Inc",1968,1727,241,,,"August 15, 2019",,
2022-14674,,,Incyte Corp,4164,4015,149,"December 13, 2008",,"May 6, 2020",the date the investigational new drug application became effective,
2022-14930,,,"Genentech, Inc",2495,2128,367,,,"August 14, 2020",,
2022-14916,,"9,273,141","Glaxo Group Ltd, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",2352,2107,245,"February 28, 2014",,"August 5, 2020",the date the investigational new drug application became effective,803
2022-15679,,"8,932,557","Eli Lilly and Company, and the USPTO requested FDA's assistance in determining the patent's eligibility for patent term restoration",3067,2825,242,"January 6, 2012",,"May 28, 2020",the date the investigational new drug application became effective,1102
2022-15823,,,"Alkermes Pharma Ireland Limited, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",1944,1623,321,,,"October 29, 2019",the new drug application (NDA) for VUMERITY (NDA 211855),
2022-16385,,"8,058,229; 8,343,933; 8,361,957",Acceleron Pharma Inc,3041,2822,219,,,"November 8, 2019",the date the investigational biologics license application became effective,
2022-16504,,,"Genentech, Inc",1968,1727,241,,,"August 15, 2019",,
2022-18753,,,"Allergan Sales LLC, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",534772883,2520,363,,,"December 23, 2019",NDA 211765,
2022-18754,,,TherOx Inc,7386,6824,562,,,"April 2, 2019",PMA P170027,
2022-19506,,,"Neurocrine Biosciences, Inc",5452,5117,335,"August 21, 2003",,"July 23, 2018",the date the investigational new drug application became effective,
2022-19714,,"7,423,050","Eli Lilly and Company, and the USPTO requested FDA's assistance in determining the patent's eligibility for patent term restoration",3097,2619,478,"August 11, 2011",,"October 11, 2019, and that the Drug Enforcement Administration issued an interim final rule controlling the product on January 31, 2020",the date the investigational new drug application became effective,1786
2022-19723,,,"Contura A/S, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",4529,3617,912,,,"January 28, 2020","the premarket approval application 
                    

      ( print page 56064)
    
                    (PMA) for BULKAMID URETHRAL BULKING SYSTEM (PMA P170023)",
2022-19898,,,"Intra-Cellular Therapies, Inc",4421,3970,451,"November 15, 2007",,"December 20, 2019",the date the investigational new drug application became effective,
2022-19993,,"7,449,458","Rigel Pharmaceuticals, Inc",4564,4198,366,,,"April 17, 2018","the date the investigational 
                    

      ( print page 56689)
    
                    new drug application became effective",
2022-20634,,,Biohaven Pharmaceutical Holding Company Ltd,3390,3144,246,,,"February 27, 2020",the new drug application (NDA) for NURTEC ODT (NDA 212728),
2022-24217,,,Kyowa Kirin Co,7300,2792,4508,,,"August 27, 2019",,
2022-24216,,"6,609,023","Angel Medical Systems, Inc",4037,2916,1121,,,"April 9, 2018","the date the investigational device exemption (IDE) for human tests to begin, as required under section 520(g) of the FD&C Act, became effective March 23, 2007.
                

                    2. 
                    The date an application",1827
2022-24457,,"7,598,279",SK Biopharmaceuticals Co,5326,4850,476,"August 12, 2005",,"November 21, 2019, and that the date of issuance of the interim final rule controlling the drug under section 201(j) of the Controlled Substances Act (21 U",the date the investigational new drug application became effective,
2022-24434,,"7,731,941","Kyushu University, National University Corporation, and the USPTO requested FDA's assistance in determining the patent's eligibility for patent term restoration",4631,4395,236,,,"December 20, 2019",NDA 209569,1375
2022-24431,,"7,335,799","Esperion Therapeutics, Inc",3774,3408,366,"October 24, 2009",,"February 21, 2020",the date the investigational new drug application became effective,1826
2022-24718,,RE46791,"AiCuris Anti-infective Cures GmbH, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",467912099393157,2911,246,,,"November 8, 2017",NDA 209939 for PREVYMIS,
2022-24719,,"8,513,255",AiCuris Anti-infective Cures GmbH and the USPTO requested FDA's assistance in determining the patent's eligibility for patent term restoration,2099403157,2911,246,,,"November 8, 2017",the NDA for PREVYMIS IV Solution (NDA 209940),894
2023-01220,,"9,827,251","Acacia Pharma Limited, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",4482,3931,551,"July 1, 2008",,"October 6, 2020",the date the investigational new drug application became effective,796
2023-02441,,"8,158,616",Eli Lilly and Co,3649,2781,868,"June 5, 2008",,"May 31, 2018",the date the investigational new drug application became effective,723
2023-02452,,,SARcode Bioscience Inc,2883,2380,503,"August 21, 2008",,"July 11, 2016",the date the investigational new drug application became effective,
2023-02482,,"7,638,536",Astellas Pharma Inc,4632,4389,243,,,"May 21, 2018",the new drug application (NDA) for DOPTELET (NDA 210238),1826
2023-02498,,,"Theravance Biopharma R&D IP, LLC and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",1724,1362,362,"February 21, 2014",,"November 9, 2018",the date the investigational new drug application became effective,
2023-02680,,,"Boehringer Ingelheim International GmbH, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",2582,2216,366,,,"April 23, 2019",the biologic license application (BLA) for SKYRIZI (BLA 761105),
2023-02667,,,ZS Pharma Inc,2384,1295,1089,,,"May 18, 2018",NDA 207078,
2023-02669,,"8,233,987","Respicardia, Inc",3685,3289,396,,,"October 6, 2017",the premarket approval application (PMA) for REMEDE SYSTEM (PMA 160039),301
2023-02745,,,Astellas Pharma Inc,2002,1757,245,"June 7, 2013",,"November 28, 2018",the date the investigational new drug application became effective,
2023-02743,,,"The Regents of the University of California, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",2795,2667,128,,,"February 14, 2018",the new drug application (NDA) for ERLEADA (NDA 210951),
2023-03070,,,Bayer Intellectual Property GmbH and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration,3004,2821,183,"June 26, 2009",,"September 14, 2017",the date the investigational new drug application became effective,
2023-04177,,"7,855,211","Eli Lilly and Company, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",2907,2760,147,"October 15, 2009",,"September 28, 2017",the date the investigational new drug application became effective,652
2023-04178,,,Nicox S,3879,3043,836,"March 23, 2007",,"November 2, 2017",the date the investigational new drug application became effective,
2023-05570,,"7,632,921","Bayer HealthCare LLC, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",2991,2626,365,"June 23, 2010",,"August 29, 2018",the date the investigational new drug application became effective,1677
2023-05641,,"9,005,281","AcuFocus, Inc",81341,827,514,,,"July 22, 2022","the date the investigational device exemption (IDE) for human tests to begin, as required under section 520(g) of the FD&C Act, became effective November 21, 2018.
                

                    2. 
                    The date an application",928
2023-05658,,"8,536,126","Novo Nordisk A/S, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",3129,2771,358,"July 29, 2010",,"February 19, 2019",the date the investigational new drug application became effective,1170
2023-05799,,,Shionogi & Co,3464,3246,218,"February 6, 2009",,"July 31, 2018",the date the investigational new drug application became effective,
2023-05897,,,"Amicus Therapeutics, Inc",5132,4891,241,"July 24, 2004",,"August 10, 2018",the date the investigational new drug application became effective,
2023-05906,,,"Ionis Pharmaceuticals, Inc",2158,1824,334,"November 9, 2012",,"October 5, 2018",the date the investigational new drug application became effective,
2023-05908,,"8,367,353","Ventana Medical Systems, Inc",181,0,181,,,"March 10, 2020",PMA P190024,547
2023-05948,,"9,029,140",Avita Medical Ltd,4455,4097,358,,,"September 20, 2018",the biologic device marketing application (BP) for RECELL AUTOLOGOUS CELL HARVESTING DEVICE (BP170122),793
2023-06580,,"8,377,138","Spinal Kinetics, Inc",64081,3617,464,,,"February 6, 2019",the premarket approval application (PMA) for M6-C ARTIFICIAL CERVICAL DISC (PMA 170036),
2023-09891,,"10,383,961","Somscan APS, and the USPTO requested FDA's assistance in determining the patent's eligibility for patent term restoration",989,744,245,,,"September 3, 2020",the new drug application (NDA) for Detectnet (NDA 213227),312
2023-10316,,"8,383,596","Achaogen, Inc",3447,3203,244,"January 18, 2009",,"June 25, 2018",the date the investigational new drug application became effective,389
2023-10295,,,Ablynx N,2998,2752,246,"November 24, 2010",,"February 6, 2019",the date the investigational new drug application became effective,
2023-10317,,,"Alnylam Pharmaceuticals, Inc",1901,1658,243,,,"August 10, 2018",the new drug application (NDA) for Onpattro (NDA 210922),
2023-10297,,,"INTACT VASCULAR, INC",61338,1114,224,,,"April 11, 2019","the date the investigational device exemption (IDE) for human tests to begin, as required under section 520(g) of the FD&C Act, became effective August 14, 2015.
                

                    2. 
                    The date an application",
2023-10979,,,,2494,2128,366,,,,,
2023-16614,,,"Intrinsic Therapeutics, Inc",2980,2163,817,,,"February 8, 2019","the date the first clinical investigation in human subjects involving the BARRICAID ANULAR CLOSURE DEVICE as part of a clinical investigation filed with FDA to secure premarket approval of the device began December 14, 2010.
                

                    2. 
                    The date an application",
2023-16607,,"8,486,975",Merck Canada Inc,2108062549,2237,312,,,"August 30, 2018",the new drug application (NDA) for PIFELTRO—NDA 210806,
2023-16606,,"8,486,975",Merck Canada Inc,2108072549,2237,312,,,"August 30, 2018",the new drug application (NDA) for DELSTRIGO (NDA 210807),328
2023-16610,,"8,321,025",Boston Scientific Neuromodulation Corp,393,0,393,,,"January 18, 2019",the premarket approval application (PMA) for VERCISE DBS SYSTEM (PMA P150031 Supplement 002 (S002)),392
2023-17259,,"8,606,362","Boston Scientific Neuromodulation Corporation, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",274,0,54617274,,,"January 21, 2021",the premarket approval application (PMA) for VERCISE GENUS DBS SYSTEM,273
2023-24124,,"9,566,260",Children's Medical Center Corporation and the USPTO requested FDA's assistance in determining the patent's eligibility for patent term restoration,4246,4007,239,"December 13, 2006",,"July 27, 2018",the date the investigational new drug application became effective,383
2023-25489,,,"Genentech, Inc",1968,,,,,,,
2023-26106,,"7,402,564","Cara Therapeutics, Inc",4625,4381,244,,,"August 23, 2021",the new drug application (NDA) for Korsuva (NDA 214916),1827
2023-26099,,,"ChemoCentryx, Inc",2642,2184,458,"July 16, 2014",,"October 7, 2021",the date the investigational new drug application became effective,
2023-26098,,,"GI Therapeutics, Inc",2081,1838,243,"June 5, 2015",,"February 12, 2021",the date the investigational new drug application became effective,
2023-26097,,"8,481,573",Scripps Research Institute and the USPTO requested FDA's assistance in determining the patent's eligibility for patent term restoration,3383,3016,367,,,"March 25, 2020",the new drug application (NDA) for Zeposia (NDA 209899),1410
2023-26247,,"7,332,472",Aurinia Pharmaceuticals Inc,7584,7338,246,"April 20, 2000",,"January 22, 2021",the date the investigational new drug application became effective,
2023-26258,,,"Myovant Sciences on behalf of Takeda Pharmaceutical Company Limited, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",4875,4632,243,"August 16, 2007",,"December 18, 2020",the date the investigational new drug application became effective,
2023-26251,,"8,436,180",Bayer Intellectual Property GmbH and the USPTO requested FDA's assistance in determining the patent's eligibility for patent term restoration,2950,2707,243,"June 13, 2013",,"July 9, 2021",the date the investigational new drug application became effective,1597
2023-26255,,,"Apellis Pharmaceuticals, Inc",2501,2258,243,"July 11, 2014",,"May 14, 2021",the date the investigational new drug application became effective,
2023-26253,,,"Trevena, Inc",3206,2112,1094,,,"August 7, 2020, and the date of issuance of the interim final rule controlling the drug under section 201(j) of the Controlled Substances Act was October 30, 2020",the new drug application (NDA) for Olinvyk (NDA 210730),
2023-26261,,,"Progenics Pharmaceuticals, Inc",2681,834092441,240,,,"May 26, 2021",the new drug application (NDA) for PYLARIFY (NDA 214793),
2023-26246,,"9,079,928","KemPharm, Inc",1676,1244,432,,,"March 2, 2021; however, the Drug Enforcement Agency issued an interim final rule controlling the product under section 201(j) of the Controlled Substances Act on May 7, 2021",the new drug application (NDA) for Azstarys (NDA 212994),948
2023-26256,,,Array BioPharma Inc,4653,4533,120,"July 24, 2007",,"April 17, 2020",NDA 213411,
2023-26260,,"10,442,847","Zealand Pharma A/S, and the USPTO requested FDA's assistance in determining the patent's eligibility for patent term restoration",1734,1373,361,,,"March 22, 2021",the new drug application (NDA) for ZEGALOGUE (NDA 214231),47
2023-26301,,,"Supernus Pharmaceuticals, Inc",4328,3816,512,"May 29, 2009",,"April 2, 2021",the date the investigational new drug application became effective,
2023-26324,,,AstraZeneca AB and Array BioPharma Inc,5100,4889,211,"April 26, 2006",,"April 10, 2020",the date the investigational new drug application became effective,
2023-26358,,"8,357,693","Kadmon Pharmaceuticals, LLC (agent for Surface Logix, LLC), and the USPTO requested FDA's assistance in determining the patent's eligibility for patent term restoration",4327,4037,290,,,"July 16, 2021",the new drug application (NDA) for Rezurock (NDA 214783),1154
2023-26303,,,"Rhizen Pharmaceuticals SA, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",2963,2727,236,"December 28, 2012",,"February 5, 2021",the date the investigational new drug application became effective,
2023-26299,,,"The University of Western Australia, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",452412,2166,246,"July 22, 2014",,"February 25, 2021",the date the investigational new drug application became effective,
2023-26363,,"7,553,828","Paratek Pharmaceuticals, Inc",2098174361,4118,243,,,"October 2, 2018",the NDA for Nuzyra Injection (NDA 209817),1812
2023-26885,,"8,552,002","QED Therapeutics, Inc",4258,4016,242,"October 2, 2009",,"May 28, 2021",the date the investigational new drug application became effective,1516
2023-26992,,,"Genmab A/S, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",2959,2736,223,,,"September 20, 2021",the biologics license application (BLA) for Tivdak (BLA B761208),
2023-26996,,,Incyte Corp,1971,1770,201,"November 26, 2014",,"April 17, 2020",the date the investigational new drug application became effective,
2023-27004,,,Takeda Pharmaceutical Company Limited and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration,2059,1857,202,"January 28, 2016",,"September 15, 2021",the date the investigational new drug application became effective,
2023-26997,,,"AVEO Pharmaceuticals, Inc",5035,4690,345,"May 30, 2007",,"March 10, 2021",the date the investigational new drug application became effective,1826
2023-26988,,"7,732,430",Mayne Pharma LLC and the USPTO requested FDA's assistance in determining the patent's eligibility for patent term restoration,1732,1366,366,"July 20, 2016",,"April 15, 2021",the date the investigational new drug application became effective,1048
2023-26982,,"9,931,414",ADC Therapeutics S,1969,1754,215,"December 4, 2015",,"April 23, 2021",the date the investigational new drug application became effective,559
2023-27003,,"8,318,706","Paratek Pharmaceuticals, Inc",2946,2599,347,,,"October 1, 2018",the new drug application (NDA) for SEYSARA (NDA 209521),1227
2023-27012,,"7,772,243",Warner-Lambert Co,4794,4554,240,,,"September 27, 2018",the new drug application (NDA) for VIZIMPRO (NDA 211288),1493
2023-27013,,"9,079,934",Nippon Shinyaku Co,1573,1255,318,,,"August 12, 2020",NDA 212154,1077
2023-26989,,"9,265,740","Paratek Pharmaceuticals, Inc",2098164361,4118,243,,,"October 2, 2018",the NDA for Nuzyra Tablets (NDA 209816),597
2023-27044,,,"Peloton Therapeutics, Inc, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",1752,1541,211,"October 28, 2016",,"August 13, 2021",the date the investigational new drug application became effective,
2023-28094,,,Alkermes Inc,4564,4003,561,"November 30, 2008",,"May 28, 2021",the date the investigational new drug application became effective,
2023-28233,,"9,505,838","Eli Lilly and Company, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",2738,2372,366,"April 1, 2011",,"September 27, 2018",the date the investigational new drug application became effective,403
2023-28244,,"8,193,182","Verastem, Inc",2596,2364,232,,,"September 24, 2018",the new drug application (NDA) for Copiktra (NDA 211155),954
2023-28509,,RE43728,Actelion Pharmaceuticals Ltd,4459,4092,367,"January 4, 2009",,"March 18, 2021",the date the investigational new drug application became effective,
2023-28507,,"9,061,057","Purdue Research Foundation, and the USPTO requested FDA's assistance in determining the patent's eligibility for patent term restoration",2610,2274,336,,,"November 29, 2021",the new drug application (NDA) for CYTALUX (NDA 214907),825
2023-28511,,,"the Government of the United States of America as represented by the Department of Health and Human Services; the Regents of the University of Michigan; Progeria Research Foundation, Inc",5023,4777,246,"February 21, 2007",,"November 20, 2020",the date the investigational new drug application became effective,
2023-28519,,"8,829,195","Novartis AG, and the USPTO requested FDA's assistance in determining the patent's eligibility for patent term restoration",2845,2717,128,,,"October 29, 2021",the new drug application (NDA) for SCEMBLIX (NDA 215358),899
2024-01439,,"8,410,103",ViiV Healthcare Company and Shionogi & Co,4719,4085,634,"February 22, 2008",,"January 21, 2021",the date the investigational new drug application became effective,1742
2024-01438,,"8,410,103",ViiV Healthcare Company and the USPTO requested FDA's assistance in determining the patent's eligibility for patent term restoration,4719,4085,634,"February 22, 2008",,"January 21, 2021",the date the investigational new drug application became effective,1742
2024-03031,,,"Ascendis Pharma Endocrinology Division A/S, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",2133,1706,427,"October 25, 2015",,"August 25, 2021",the date the investigational new drug application became effective,
2024-03019,,,Merck Sharp & Dohme Corp,3374,3130,244,"July 5, 2012
                

                    2",,"September 28, 2021",the date the investigational new drug application became effective,
2024-03030,,"8,012,489",Merck Sharp & Dohme Corp,1941,1783,158,,,"December 19, 2019",the biologics license application (BLA) for ERVEBO (BLA 125690),1038
2024-03022,,,Cassiopea S,3102,2736,366,"March 1, 2012",,"August 26, 2020",the date the investigational new drug application became effective,
2024-03025,,"9,522,274","MicroTransponder, Inc",2719,2540,179,,,"August 27, 2021","the date the investigational device exemption for human tests to begin, as required under section 520(g) of the FD&C Act, became effective March 20, 2014.
                

                    2. 
                    The date an application",1359
2024-03026,,,"Mainstay Medical Limited, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",81729,1436,293,,,"June 16, 2020","the date the investigational device exemption for human tests to begin, as required under section 520(g) of the FD&C Act, became effective September 24, 2015.
                

                    2. 
                    The date an application",
2024-03024,,,Simplify Medical Pty Ltd,2020,1842,178,,,"September 18, 2020","the date the investigational device exemption for human tests to begin, as required under section 520(g) of the FD&C Act, became effective March 11, 2015.
                

                    2. 
                    The date an application",
2024-03028,,"7,651,835","TransMedics, Inc",5518,4535,983,,,"September 3, 2021","the date the investigational device exemption for human tests to begin, as required under section 520(g) of the FD&C Act, became effective July 28, 2006.
                

                    2. 
                    The date an application",1826
2024-03034,,"10,076,112","TransMedics, Inc",2275,1819,456,,,"September 28, 2021","the date the investigational device exemption for human tests to begin, as required under section 520(g) of the FD&C Act, became effective July 9, 2015.
                

                    2. 
                    The date an application",72
2024-03029,,,St,3028,2288,740,,,"September 17, 2021","the date the investigational device exemption for human tests to begin, as required under section 520(g) of the FD&C Act, became effective June 5, 2013.
                

                    2. 
                    The date an application",
2024-03032,,,"Intact Vascular, Inc",415451203,1010,193,,,"April 10, 2020",PMA P190027,
2024-03961,,"9,593,164","Janssen Biotech, Inc",1284,1105,179,,,"May 21, 2021",the biologics license application (BLA) for Rybrevant (BLA B761210),546
2024-04226,,"7,504,095","Origin Biosciences, Inc",2815,2572,243,"June 15, 2013",,"February 26, 2021",the date the investigational new drug application became effective,1529
2024-04231,,,"Recordati AG, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",4393,4026,367,,,"March 6, 2020",the new drug application (NDA) for ISTURISA (NDA 212801),
2024-04219,,,"Bristol-Myers Squibb Company, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",3110,2867,243,"September 13, 2013",,"March 18, 2022",the date the investigational new drug application became effective,552
2024-04157,,"9,474,780","Eli Lilly and Company, and the USPTO requested FDA's assistance in determining the patent's eligibility for patent term restoration",2208,1967,241,"April 28, 2016",,"May 13, 2022",the date the investigational new drug application became effective,129
2024-04208,,"8,779,109","Novo Nordisk Health Care AG, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",2200,1833,367,"August 22, 2014",,"August 28, 2020",the date the investigational new drug application became effective,1284
2024-04232,,,Athenex Inc,4899,4548,351,"July 19, 2007",,"December 14, 2020",the date the investigational new drug application became effective,
2024-04205,,"9,303,051","Chimerix, Inc",5463,5222,241,"June 22, 2006",,"June 4, 2021",the date the investigational new drug application became effective,1064
2024-04203,,,AstraZeneca AB (agent of E,4578,4213,365,"January 18, 2009",,"July 30, 2021",the date the investigational new drug application became effective,
2024-04207,,"9,018,356","Regeneron, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",3002,2756,246,"November 25, 2012",,"February 11, 2021",the date the investigational new drug application became effective,972
2024-04162,,,CTI BioPharma Corp,5138,4802,336,"February 6, 2008",,"February 28, 2022",the date the investigational new drug application became effective,
2024-04214,,,"University of Zurich, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",3689,3353,336,"May 4, 2011",,"June 7, 2021",the date the investigational new drug application became effective,634
2024-04156,,"9,918,984","Xeris Pharmaceuticals, Inc",5812,5507,305,,,"December 30, 2021",the new drug application (NDA) for RECORLEV (NDA 214133),844
2024-04224,,,"Gilead Sciences, Inc",1904,1827,77,"August 8, 2015",,"October 22, 2020",the date the investigational new drug application became effective,
2024-04217,,"9,586,955","Genentech, Inc",1368,1049,319,"November 10, 2016",,"August 7, 2020",the date the investigational new drug application became effective,
2024-04150,,"8,188,085","Scynexis, Inc",4130,3886,244,"February 11, 2010",,"June 1, 2021",the date the investigational new drug application became effective,1768
2024-04165,,,"Myokardia, Inc",2723,2266,457,"November 16, 2014",,"April 28, 2022",the date the investigational new drug application became effective,
2024-04221,,,"Urovant Sciences GmbH, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",3953,3589,364,"February 28, 2010",,"December 23, 2020",the date the investigational new drug application became effective,
2024-04227,,"8,906,887","Tetraphase Pharmaceutical, Inc",3265,3022,243,,,"August 27, 2018",the new drug application (NDA) for XERAVA (NDA 211109),608
2024-04218,,,Foresee Pharmaceutials Co,2569,2266,303,,,"May 25, 2021",the new drug application (NDA) for CAMCEVI (NDA 211488),
2024-04230,,,"Novartis Pharmaceuticals Corporation, and the USPTO requested FDA's assistance in determining the patent's eligibility for patent term restoration",2134,1403,731,"February 20, 2016",,"December 22, 2021",the date the investigational new drug application became effective,
2024-04233,,,Bial-Portela & CA,3306,2940,366,,,"April 24, 2020",the new drug application (NDA) for ONGENTYS (NDA 212489),
2024-04234,,,Otsuka Pharmaceutical Co,2330,2120,210,"February 21, 2014",,"July 7, 2020",the date the investigational new drug application became effective,
2024-04206,,,St,1846,1619,227,,,"August 14, 2021",PMA P200049,
2024-04229,,"7,935,787","Wyeth LLC, and (U",201678,1434,244,"November 5, 2016",,"June 8, 2021",the date the investigational new drug application became effective,
2024-04204,,,"AtriCure, Inc",2919,2436,483,,,"April 28, 2021","the date the investigational device exemption for human tests to begin, as required under section 520(g) of the FD&C Act, became effective May 3, 2013.
                

                    2. 
                    The date an application",
2024-04480,,,Amylyx Pharmaceuticals Inc,3359,3023,336,,,"September 29, 2022",the new drug application (NDA) for RELYVRIO (NDA 216660),
2024-04481,,"8,911,786","Aadi Bioscience, Inc",5416,5237,179,"January 26, 2007",,"November 22, 2021",the date the investigational new drug application became effective,1357
2024-04483,,"RE47,929","Bristol-Myers Squibb Company, and the USPTO requested FDA's assistance in determining the patent's eligibility for patent term restoration",2136,1770,366,"November 6, 2016",,"September 9, 2022",the date the investigational new drug application became effective,1037
2024-04479,,"8,198,242",BioMarin Pharmaceutical Inc,3614,3157,457,,,"November 19, 2021",the new drug application (NDA) for VOXZOGO (NDA 214938),1826
2024-04478,,"7,780,723","Edwards Lifesciences Corporation, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",3101,0,101,,,"December 27, 2018",PMA P140031S074,184
2024-05213,,,"RxSight, Inc",3346,3031,315,,,"November 22, 2017",PMA P160055,
2024-05305,,,"Pfizer, Inc",3388,3179,209,,,"November 21, 2018",the new drug application (NDA) for DAURISMO (NDA 210656),
2024-05407,,,"Agios Pharmaceuticals, Inc",2885,2639,246,"March 28, 2014",,"February 17, 2022",the date the investigational new drug application became effective,
2024-05408,,"10,195,160","Dermavant Sciences, GmbH and the USPTO requested FDA's assistance in determining the patent's eligibility for patent term restoration",3134,2771,363,"October 25, 2013",,"May 23, 2022",the date the investigational new drug application became effective,4
2024-05421,,,PFIZER Inc,3173,2665,508,,,"January 14, 2022",the new drug application (NDA) for CIBINQO (NDA 213871),
2024-10361,,,"GlaxoSmithKline (agent for AnaptysBio, Inc",1919,1428,491,"January 22, 2016",,"April 22, 2021",the date the investigational new drug application became effective,
2024-14536,,,Protalix Ltd,3927,2849,1078,"August 9, 2012",,"May 9, 2023",the date the investigational new drug application became effective,
2024-14538,,,"Genzyme Corporation and Icahn School of Medicine at Mount Sinai, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",5971,5669,302,,,"August 31, 2022",the biologics license application (BLA) for XENPOZYME (BLA 761261),
2024-14577,,,Amgen Inc,4848,4623,225,"September 10, 2008",,"December 17, 2021",the date the investigational new drug application became effective,
2024-14532,,,"The Board of Regents of 
                    

      ( print page 54834)
    
                    the University of Texas System, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",1710,1344,366,"April 14, 2017",,"December 17, 2021",the date the investigational new drug application became effective,
2024-14540,,"8,519,100",Immunocore Ltd,3641,3424,217,"February 8, 2012",,"January 25, 2022",the date the investigational new drug application became effective,1739
2024-14541,,"10,577,422","Incyte Corporation (Agent of MacroGenics, Inc",2372,2145,227,"September 24, 2016",,"March 22, 2023",the date the investigational new drug application became effective,138
2024-14535,,"10,072,088","Janssen Biotech, Inc",2050,1748,302,"March 17, 2017",,"October 25, 2022",the date the investigational new drug application became effective,70
2024-14723,,"10,233,243","UCB Biopharma SRL, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",2283,2036,247,,,"June 26, 2023",the biologics license application (BLA) for RYSTIGGO (BLA 761286),902
2024-14720,,,"Genentech, Inc",3046,2800,246,"September 28, 2013",,"January 28, 2022",the date the investigational new drug application became effective,
2024-14729,,,Bioverativ USA Inc,1845,1151,694,"January 18, 2017",,"February 4, 2022",the date the investigational new drug application became effective,766825
2024-14728,,,"Genentech, Inc",2809,2571,238,"April 16, 2015",,"December 22, 2022",the date the investigational new drug application became effective,
2024-14732,,,"Revance Therapeutics, Inc",2339,1321,1018,,,"September 7, 2022",the biologics license application (BLA) for DAXXIFY (BLA 761127),
2024-14716,,,"AstraZeneca AB, and the USPTO requested FDA's assistance in determining this patents' eligibility for patent term restoration",7634,7393,241,"November 28, 2001",,"October 21, 2022",the date the investigational new drug application became effective,
2024-15239,,"9,023,995","Boehringer Ingelheim International GmbH, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",1729,1393,336,"December 9, 2017",,"September 1, 2022",the date the investigational new drug application became effective,1033
2024-15998,,,,,,,,,,,
2024-17511,,"9,834,539","Forma Therapeutics, Inc",2563,2273,290,,,"December 1, 2022",the new drug application (NDA) for REZLIDHIA (NDA 215814),440
2024-17648,,"8,987,441",Shionogi & Co,985,801,184,,,"October 24, 2018",the new drug application (NDA) for XOFLUZA (NDA 210854),399
2024-17643,,"8,012,976","Medivation Technologies LLC, and the USPTO requested FDA's assistance in determining this patent's eligibility for patent term restoration",2869,2675,194,"December 10, 2010",,"October 16, 2018",the date the investigational new drug application became effective,1093
2024-17639,,"7,781,577 and 8,217,156","Lexicon Pharmaceuticals, Inc",5268,4903,365,"December 24, 2008",,"May 26, 2023",the date the investigational new drug application became effective,
2024-17510,,,"Ambit Biosciences Corporation, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",6110,5779,331,"October 29, 2006",,"July 20, 2023",the date the investigational new drug application became effective,
2024-18265,,,"Novaliq GmbH, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",2018,1693,325,"November 9, 2017",,"May 18, 2023",the date the investigational new drug application became effective,
2024-20149,,"8,080,580",Pfizer Inc,2976,2610,366,,,"December 19, 2017",the new drug application (NDA) for STEGLATRO (NDA 209803),524
2024-20150,,,Pfizer Inc,2976,2610,366,,,"December 19, 2017",the new drug application (NDA) for STEGLUJAN (NDA 209805),
2024-20115,,"11,052,064","Verrica Pharmaceuticals, and the USPTO requested FDA's assistance in determining the patent's eligibility for patent term restoration",2285,877,1408,"April 20, 2017",,"July 21, 2023",the date the investigational new drug application became effective,745
2024-20148,,,Pfizer Inc,2976,2610,366,,,"December 19, 2017",the new drug application (NDA) for SEGLUROMET (NDA 209806),
2024-20246,,"10,398,791","Advanced Accelerator Applications USA, Inc",1881,1643,238,"January 29, 2017",,"March 23, 2022",the date the investigational new drug application became effective,523
2024-20555,,"7,722,856",Cyclomedica Australia Pty Limited and the USPTO requested FDA's assistance in determining the patent's eligibility for patent term restoration,4322,3039,1283,"December 1, 2011",,"September 29, 2023",the date the investigational new drug application became effective,1826
2024-20549,,"8,318,714","Marinus Pharmaceuticals, Inc",10382,10065,317,"December 30, 1993",,"March 18, 2022, and that the Drug Enforcement Agency issued an interim final rule controlling the product under section 201(j) of the Controlled Substances Act on June 1, 2022",the date the investigational new drug application became effective,
2024-20552,,"7,977,488","Phathom Pharmaceuticals, Inc",215152971,727,244,,,"May 3, 2022 4:37 p",the NDA for VOQUEZNA TRIPLE PAK—NDA 215152,599
2024-20551,,"7,977,488","Phathom Pharmaceuticals, Inc",215153971,727,244,,,"May 3, 2022 4:37 p",the new drug application (NDA) for VOQUEZNA DUAL PAK—NDA 215153 (NDA 215153),
2024-20894,,,"Cidara Therapeutics, Inc",2814,2570,244,"July 10, 2015",,"March 22, 2023",the date the investigational new drug application became effective,
2024-20893,,,,2965,2740,225,"December 17, 2014",,"January 27, 2023",,
2024-21677,,,Vertex Pharmaceuticals Inc,2832,2602,230,,,"February 12, 2018",the new drug application (NDA) for SYMDEKO (NDA 210491),
2024-21836,,"9,732,075",Idorsia Pharmaceuticals Ltd,2115,1660,455,"June 24, 2016",,,the date the investigational new drug application became effective,1030
2024-21844,,,"GlaxoSmithKline LLC, and the USPTO requested FDA's assistance in determining the patents' eligibility for patent term restoration",5127,4670,457,"September 3, 2009",,"September 15, 2023",the date the investigational new drug application became effective,
2024-21841,,,,1548,1510,38,,,,,
2024-21847,,"8,648,097; 8,685,986; 10,702,511",Santen Pharmaceutical Co,3723,3050,673,"July 15, 2012",,"September 22, 2022",the date the investigational new drug application became effective,
2024-21963,,"8,481,546",Pfizer Inc,1619,1253,366,"October 4, 2018",,"March 9, 2023",the date the investigational new drug application became effective,993
2024-21848,,"8,324,208","GlaxoSmithKline LLC, and the USPTO requested FDA's assistance in determining the patent's eligibility for patent term restoration",5328,4962,366,,,"February 1, 2023",the new drug application (NDA) for JESDUVROQ (NDA 216951),2038
2024-21941,,"9,212,204",Acadia Pharmaceuticals Inc,5106,4864,242,,,"March 10, 2023",the new drug application (NDA) for DAYBUE (NDA 217026),1443
2024-21929,,"8,114,863",Guerbet LLC and the USPTO requested FDA's assistance in determining the patent's eligibility for patent term restoration,2443,2199,244,"January 15, 2016",,"September 21, 2022",the date the investigational new drug application became effective,1344
2024-21930,,,HUTCHMED LTD,2604,2380,224,"September 23, 2016",,"November 8, 2023",the new drug application (NDA) for FRUZAQLA (NDA 217564),
2024-22105,,,SpringWorks Therapeutics Inc,5425,5089,336,"January 21, 2009",,"November 27, 2023",the new drug application (NDA) for OGSIVEO (NDA 217677),
